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ABSTRACT
Malignant mesothelioma (MM) is a rare, usually incurable, disease mainly caused by former 
exposure to asbestos. Even though MM has a strong etiological link, genetic factors may play 
a role, since not all cases can be linked to former asbestos exposure. This thesis focuses on 
lung diseases, mainly pleural MM, and asbestosis/fibrosis, attributable to asbestos exposure. 
The specific asbestos-related pathways associated with malignant as well as non-malignant 
lung diseases, still need to be clarified. Several hypotheses about how asbestos acts and 
damages cells as well as the pathways and genes involved in disease progression have been 
proposed. Since most patients diagnosed with MM or asbestosis/fibrosis have a dismal 
prognosis and few therapeutic options are available, early diagnosis and better understanding 
of the disease pathogenesis are of the utmost importance. 
Expression profiling of asbestos specific differentially expressed genes was approached using 
high-resolution  arrays,  three  different  human  lung  cell  lines  as  well  as  with  three  different  
bioinformatics approaches. Several different profiling strategies were applied to try to 
identify asbestos relevant expression changes. Bioinformatics probed the genes and 
biological processes ordered in terms of significance, clusters, and highly enriched 
chromosomal regions. The study revealed several already identified targets, produced new 
ideas about genes which are central for asbestos exposure as well as providing supplementary 
data for researchers to check their own novel findings or ideas.  
Since the first study aimed to elucidate potential early changes, the second study was used to 
screen  DNA  copy  number  changes  in  MM  tumour  samples.  This  was  performed  using  
genome wide microarrays for identification of copy number changes specific for MM and 
potentially for asbestos. The analysis revealed considerably more DNA copy number losses 
than gains, and pinpointed more precise chromosomal regions of DNA copy number changes 
for further validation. The most common regions of loss were detected in 1p, 3p, 6q, 9p, 13, 
14, and 22, and gains at 17q.
Study III focused on the role of gremlin in the regulation of BMP signaling in idiopathic 
pulmonary fibrosis (IPF). The bone morphogenetic protein (BMP) antagonist gremlin was 
up-regulated by asbestos exposure in human epithelial cell lines, which was also observed in 
Abstract 
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Study I. Further studies were conducted in asbestos-exposed cell cultures as well as in an 
asbestos-induced mouse model. The histological features in asbestosis and IPF are very 
similar, therefore asbestos models can be used. The transforming growth factor (TGF) - and 
BMP expression and signaling activities were measured from murine and human fibrotic 
lungs. BMP-7 signaling was down-regulated in response to up-regulation of gremlin, and 
attempts were made to restore BMP-7 signaling in the prevention of pulmonary fibrosis. 
Therefore, the study suggests that the restoration of BMP-7 signaling in fibrotic lung could 
potentially be used in treatment of IPF. 
Furthermore, GATA-6 was studied in MM and metastatic pleural adenocarcinoma. The 
GATA transcription factors are important during embryonic development, but their roles in 
cancer is still unclear. GATA-6 is a co-factor/target of thyroid transcription factor 1 (TTF-1), 
which is used in differential diagnostics of pleural MM and adenocarcinoma. GATA-6 was 
strongly expressed in the majority of the MM cases, and correlated significantly with longer 
survival in subgroups of MM. Given the over-all survival of both MM and metastatic 
adenocarcinoma, expression of GATA-6 significantly correlated with longer survival. The 
correlation between GATA-6 and TTF-1 expression in metastatic adenocarcinoma was 
further examined, but did not reveal any statistically significant correlations. 
The  aims  of  this  thesis  were  to  elucidate  some of  the  genetic  and  molecular  events  behind  
two  diseases  with  poor  prognosis.  The  focus  was  on  pleural  MM,  and  pulmonary  fibrosis,  
that can either be a result of asbestos exposure or be idiopathic. High-throughput methods for 
the molecular biology behind diseases have evolved rapidly, allowing powerful screening, 
and can pinpoint further research targets. MM and IPF patients would benefit from 
identifying biomarkers that would improve diagnostic and prognostic prediction, and 
possibly provide more targeted therapies.  
Introduction 
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INTRODUCTION 
Smoking and inhalation of airborne pollutants, and asbestos or silica, is linked to 
inflammation of the lung, fibrosis,  and cancer.  A history of exposure to asbestos fibers is  a 
recognized risk factor for MM, lung cancer, and non-neoplastic conditions, such as asbestosis 
and pleural plaques (Mossman et al. 1989; Mossman and Bignon 1990; Mossman et al. 1996; 
Wagner et al. 1960). In particular, asbestos fibers have been associated with the development 
of MM, and about 5-7 % of all lung cancers are attributable to former occupational asbestos-
exposure (LaDou 2004). However, the mechanisms whereby asbestos causes damage to cells 
of the lung and pleura and how the asbestos related diseases develop are still largely unclear. 
Inflammation is a characteristic feature for exposure to asbestos and has been observed both 
in animal models and in the lungs of patients with asbestos-related lung disease (Kamp and 
Weitzman 1999; Mossman and Churg 1998). Bronchial epithelial cells and alveolar 
macrophages  are  in  extensive  contact  with  the  inhaled  particles  when  trying  to  clear  them  
from the lung, and can initiate/maintain inflammatory responses.  
Although the main etiological factor for MM is asbestos fibers, the tumour can arise without 
any known asbestos exposure suggesting other initiating or genetic factors. It is important to 
understand how asbestos fibres interact with the target cells, i.e. epithelial, mesothelial and 
fibroblastic cells, and how this contributes to the pathogenesis of asbestos-associated fibro-
proliferative and malignant diseases. 
In this study, the focus is on pleural MM and idiopathic pulmonary fibrosis (IPF) that can 
either be a result of asbestos exposure or be idiopathic. The histopathological features of 
asbestosis and IPF are very similar. The study of these and other diseases is rapidly 
developing with more powerful genome-wide techniques for profiling the patient genome and 
markers for more accurate diagnosis and prognosis of disease. An important aspect 
accounting for the poor prognosis of both MM and lung fibrosis/asbestosis is the resistance to 
any treatment modalities. Therefore, earlier detection of asbestos-related disease, and/or more 
specific treatment strategies, as well as potential blood or other non-invasive markers are of 
importance.
Review of the Literature 
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I REVIEW OF THE LITERATURE
1 ASBESTOS FIBRES  
Asbestos fibres comprise a family of crystalline mineral fibres, which are flexible, durable 
and resistant to heat and chemical erosion. There are six chemically and physically distinct 
fibres  that  are  classified,  based  upon  their  morphology,  as  serpentine  (chrysotile)  or  
amphibole (crocidolite, amosite, anthophyllite, actinolite and tremolite) (see Table 1). Due to 
the indestructible characteristics of asbestos, it has been widely used in industry (primarily 
insulation products due to heat resistance, ship-building etc), but since its use was banned in 
most developed countries in the 1970s, its use is mostly in Eastern Europe, Latin America 
and Asia (LaDou 2004; Lin et al. 2007). Preveously chrysotile has been used most often in 
industry, and since this is the type mined in Canada and parts of the US, as well as being the 
most common type of asbestos in global terms, it is an extensively studied asbestos fibre in 
experimental models. In addition, much effort has been spent on studying the properties and 
effects of crocidolite, a high iron-containing asbestos and the most pathogenic amphibole 
fibre (Mossman and Gee 1989; Mossman and Bignon 1990). The quantitative risks of MM in 
relation to asbestos fibre exposure have been evaluated as being 500:100:1 
(chrocidolite:amosite:chrysotile). The risk discrepancy between chrysotile and the two 
amphibole fibres for lung cancer is between 1:10 and 1:50 (Hodgson and Darnton 2000).  
A percentage of the asbestos fibres become coated with iron and protein when they are in the 
lung. These are referred to as asbestos bodies, and should be distinguished from ferruginous 
or iron-coated bodies. Epidemiological evidence shows that the fibre shape and length-to-
width ratio are important physical characteristics that determine how deeply into the lung the 
fibres are inhaled and whether they have the capacity to penetrate the lung epithelium and 
enter  or  irritate  the  pleural  space  (Boutin  and  Rey  1993;  Pott et al. 1987; Sebastien et al.
1980). Asbestos fibres have the capacity to interfere with the mitotic spindle, disrupting 
mitosis, which in turn may lead to aneuploidy and other forms of chromosome damage that 
characterise MM (Ault et al. 1995). The aberrant mitosis and multi-polar spindles observed 
in asbestos treated cells could lead to the incorrect chromosome segregation and result in 
aneuploid cells (Hesterberg et al. 1998; Kodama et al. 1993). Asbestos-induced cell damage 
is  also  mediated  at  least  to  some  extent  by  iron-related  reactive  oxygen  species  (ROS)  
(Koerten et al. 1990; Manning et al. 2002b; Shatos et al. 1987; Weitzman and Graceffa 1984; 
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Zanella et al. 1996), which induce DNA damage and strand breaks (Kamp et al. 1995). In 
brief, inhaled asbestos fibres which enter the lung epithelium and irritate the pleural cell 
lining, act via several different possible mechanisms, causing injury, repair and local 
inflammation. This repeated scratching may thus evoke the formation of plaques, fibrosis or 
cancer (Kamp and Weitzman 1999; Kinnula 1999; Mossman and Churg 1998).  
Table 1. Chemistry and morphology of asbestos fibres.  
Amphibole  Chemical formulae Morphology;mean 
length/diameter (cm) 
Crocidolite (Na2Fe2+3Fe3+2)       Si8O22(OH)2 Rodlike, durable; 11.4 / 0.27 
Amosite (Fe2+, Fe)7                Si8O22(OH)2 Rodlike, durable
Anthophyllite (Mg, Fe2+)7              Si8O22(OH)2 Rodlike, durable 
Tremolite Ca2Mg5                    Si8O22(OH)2 Rodlike, durable 
Actinolite Ca2(Mg, Fe2+)5        Si8O22(OH)2 -
Serpentine  Chemical formulae Morphology;mean 
length/diameter (cm) 
Chrysotile Mg6                          Si4O10(OH)8 Curly, pliable; 1.1 / 0.04 
1.1 Genes and pathways affected by asbestos fibres 
Few cancers have such a direct causal relation with the exposure to a defined carcinogen as 
MM has with asbestos exposure, and lung cancer has with cigarette smoking and/or asbestos 
fibres. The mechanisms of mesothelial and lung cell transformation by asbestos still remain 
mostly unclear, although fibre dimension and amount, surface properties, physical durability, 
cell and tissue responses, as well as the duration of the exposure time, are important criteria 
for the transformation. Asbestos directly or indirectly induces chromosomal aberrations, 
disturbed cell division, sister chromatid exchanges and deletions, harbouring multiple tumour 
suppressor genes (TSG) (Dopp and Schiffmann 1998; Jensen et  al. 1996; Mossman et al.
1997; Nygren et al. 2004; Pelin et al. 1995). As little as 48h exposure to chrysotile can cause 
centrosome amplification, apoptosis and aneuploid cell formation, even when long periods of 
recovery were provided (Cortez and Machadosantelli 2008).  
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Asbestos fibres can be co-localized from the lung interstitium by pulmonary lymph flow, 
from where they can reach the bloodstream and subsequently all organs. This slow process 
occurs over decades, and is possibly due to increased permeability caused by inflammation. 
Continuing emphasis is laid on inflammation possibly preceding various malignancies. 
Asbestos fibres cause accumulation of macrophages and consequently the release of 
interleukins and other cytokines such as tumor necrosis factor-  (TNF-) and inflammation 
is probably an early reaction in asbestos-related disease. Epidemiological studies have shown 
that chronic inflammation predisposes individuals to various types of cancer. It has been 
estimated that underlying infections and inflammatory responses can be linked to 15–20% of 
all deaths from cancer worldwide (Balkwill and Mantovani 2001). The hallmarks of cancer-
related inflammation include the presence of inflammatory cells and inflammatory mediators 
(for example, chemokines, cytokines and prostaglandins) in tumour tissues, tissue 
remodelling and angiogenesis similar to that seen in chronic inflammatory responses and 
tissue repair. The connection between inflammation and cancer could be explained by an 
extrinsic pathway, driven by inflammatory conditions with subsequent increased cancer risk; 
or an intrinsic pathway, triggered by genetic alterations that cause inflammation and cancer 
(for a review see Mantovani et al. 2008). 
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Figure 1. Pathogenesis of malignant mesothelioma. Asbestos-related pathways, leading to 
altered gene expression in mesothelial cells, as well as bronchial epithelial cells, fibroblasts 
and macrophages, causing cell injury, proliferation and eventually cancer.  
1.1.1 Oxidative stress and antioxidant pathways 
Lung irritants such as cigarette smoke and asbestos evoke a chronic stress-situation for 
human lung cells, causing oxidative stress. In addition to their capacity to damage 
macromolecules, oxidants play important roles in the initiation of signal transduction 
pathways that are linked to apoptosis, inflammation and proliferation (Shukla et al. 2003a). 
For example, oxidants contribute to asbestos-induced lung injury; therefore lung cell damage 
occurring through these pathways is important. 
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After exposure to asbestos, there is generally an inflammatory reaction with a large 
component of mononuclear phagocytes. After the cells have differentiated into macrophages, 
they phagocytize asbestos and subsequently release numerous cytokines and reactive oxygen 
species/reactive nitrogen species (ROS/RNS) that are cytotoxic and potentially clastogenic 
(Choe et al. 1997; Driscoll et al. 1997; Mongan et al. 2000; Perkins et al. 1993; Robledo and 
Mossman 1999; Xu et al. 2002; Yang et  al. 2003). These ROS/RNS produced due to the 
presence of asbestos fibres, may cause cellular toxicity and carcinogenicity possibly by 
inducing lipid peroxidation, altering signal transduction pathways, as well as damaging the 
DNA. ROS also cause the formation of 8-hydroxy-2´-deoxyguanosine (8OHdG) adducts, 
which are elevated in white blood cells of individuals with former asbestos exposure 
(Marczynski et al. 1994). The generation of oxidants by fibres or crystalline silica particles 
results in cell injury, activation of signaling pathways such as mitogen activated protein 
kinases /extracellular signal-regulated kinase (MAPK/ERK), and ERK phosphorylation, 
increased expression of inflammatory cytokines (e.g., TNF-, IL-1), and activation of 
specific transcription factors (e.g., NF-B, AP-1). Phosphorylation of the ERK1/ERK2 also 
raise expression of early response proto-oncogenes such as FOS and JUN (Manning et al.
2002a; Zanella et  al. 1996). The ERK cascade has been associated with early injury and 
subsequent proliferation of mesothelial cells (Ramos-Nino et al. 2002). The response of the 
cells to oxygen- and nitrogen-based free radicals can vary widely. Common reactions are 
mitochondrial dysfunction, and increased gene expression of death receptors, and/or their 
ligands (TNF-, Fas ligand) (for a review see Shukla et al. 2003b).  
The balance of oxidant-antioxidant pathways is crucial and disturbances in this equlibrium 
reduce the capacity of the cells to protect themselves against free radicals, i.e. their ability to 
produce sufficient antioxidant enzymes, such as superoxide dismutases (SOD), catalase 
(CAT),  and  other  H2O2 decomposing enzymes, such as gluthatione peroxidises is reduced. 
Small molecular weight antioxidants such as glutathione help to protect the cells against 
oxidative burden (Hei et al. 1995; Puhakka et al. 2002). There are several SODs e.g. MnSOD 
in the mitochondria, CuZnSOD in the cytosol (Fridovich 1986) and extracellular SOD in the 
extracellular matrix (Oury et al. 1994). Asbestos-induced depletion of glutathione is induced 
by the inhibition of the enzyme, glucose-6-phosphate dehydrogenase (G6PD) in the pentose 
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phosphate pathway. Synthetic fibres did not have the same effect, evidence that fibre surface 
features are crucial for the antioxidant effect (Golladay et al. 1997). 
Antioxidant thiol related detoxification mechanisms such as glutathione-S-transferases 
(GSTs) are also closely associated with human lung malignancies and their resistance to 
cytotoxic drugs. Enzymes directly related to GSH synthesis and thiol-containing redox 
modulator proteins thioredoxins (TRXs) or peroxiredoxins (PRXs) are often over-expressed 
in malignant diseases (for a review see Kinnula et al. 2004).
1.1.2 Nuclear factor-kappa B (NF-B) and tumor necrosis factor-  (TNF-)
Nuclear factor-kappa B (NF-B) and its signaling pathways are critical regulators for cell 
lineage development, growth, differentiation, apoptosis, and tumourigenic transformation. 
NF-B is an important transcription factor implicated in the transcriptional up-regulation of 
cytokines, adhesion molecules, growth factors, oncogenes, antiapoptotic proteins, some 
proapoptotic factors, and even certain viral genes. Asbestos induced ROS play a key role in 
enhancing the inflammation through activation and phosphorylation of the redox sensitive 
NF-B in various inflammatory diseases. It has been reported that NF-B can regulate the 
inflammatory and cell proliferative responses to asbestos (Haegens et al. 2007).
The cytokine TNF-, has been linked to asbestos pathogenesis (Miyazaki et al. 1995; 
Mossman and Churg 1998; Tanaka et al. 2000; Xie et al. 2000), though the mechanisms are 
unclear. It seems that long fibres, which are considered to be more carcinogenic and 
fibrogenic  than  short  fibres,  stimulate  a  greater  release  of  TNF- (Donaldson et al. 1993). 
When the asbestos fibres are engulfed by macrophages, they release TNF-. At the same 
time, asbestos stimulates human mesothelial cells to secrete TNF- (both paracrine and 
autocrine effects). TNF- activates NF-B that increases cell survival, and allows the cells to 
divide rather than die and, if sufficient genetic damage has accumulated, to eventually 
develop into a MM (Yang et al. 2003; Yang et al. 2006). 
The proteasome inhibitor, bortezomib, inhibits NF-B dependent survival and has strong in
vivo activity in MM (Sartore-Bianchi et al. 2007). Inhibition of NF-B constitutive activation 
in MM cells by bortezomib resulted in in vitro cytotoxicity as well as apoptosis and in vivo
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tumour decay, and suggests bortezomib as a part in the treatment of MM (Sartore-Bianchi et 
al. 2007). 
1.1.3 Epidermal growth factor receptor (EGFR) mediated pathway 
Epidermal  growth  factor  receptor  (EGFR)  is  one  of  the  ErbB  families  of  receptor  tyrosine  
kinases. EGFR expression by tumours may contribute to the growth and invasiveness of 
malignant cells (Walker 1998). Inhibition of EGFR with selective tyrosine kinase inhibitors 
or anti-EGFR antibodies results in inhibition of tumour growth not only through direct 
growth inhibitory effects on EGFR positive tumour cells but also through the inhibition of 
angiogenesis. The expression of EGFR is common in MM and has been correlated with 
favourable prognosis (Edwards et  al. 2006). EGFR activates the MAPK pathway and 
phosphorylation of ERK1/2 and -5, and it is known that asbestos causes activation of EGFR 
(Zanella et al. 1996). Phosphorylation of the ERK pathway in turn leads to activation of 
downstream targets (Shukla et al. 2004). EGFR governs acute epithelial cell proliferation and
proto-oncogene expression by asbestos, and mice expressing a dominant-negative mutant 
EGFR exhibited decreased pulmonary epithelial cell proliferation without alterations in 
asbestos-induced inflammation. Therefore targeting EGFR in preventive and therapeutic 
approaches to asbestos-induced neoplasms, could be of importance (Manning et al. 2002a). 
1.1.4 Transforming growth factor- (TGF-)
Several growth factors and their receptors drive MM proliferation; the only factors whose 
blockade has been shown to arrest MM growth are transforming growth factor- (TGF-)
and platelet-derived growth factor A chain (PDGFA) (Marzo et al. 1997). TGF- is often 
produced abundantly by many tumour types and is known to function as both a TSG as well 
as a tumour promoter (reviewed in Bierie and Moses 2006). TGF- can act through several 
mechanisms as tumour promoter e.g. dysregulation of CDK inhibitors; alteration in 
cytoskeletal architecture, which is often implicated in epithelial to mesenchymal transition 
(EMT); increases in proteases and extracellular matrix (ECM) formation; decreased 
immunosurveillance; and increased angiogenesis See chapter 3.1.1 for more information on 
TGF-.
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1.2 Asbestos-related diseases 
Although banned in most western countries, asbestos is still in wide use, and due to the long 
latency period (20-40 years), from the time of exposure to the diagnosis of the disease, the 
peak incidence is still in the future such that the numbers of cases are estimated to increase 
until 2015. Asbestos was recognized as an occupational hazard in the early 20th century, and 
even though asbestos-related MM (Wagner et al. 1960) and lung cancer (Selikoff et al. 
1968), were reported, asbestos was still widely used until the 1970s. Asbestos is associated 
with the development of asbestosis, bronchial cancer, MM of pleura and peritoneum, and to a 
more limited extent, to various gastrointestinal, oropharyngeal and laryngeal cancers. In 
asbestos-related lung cancer, tobacco smoking and asbestos have a synergistic effect 
(Selikoff and Greenberg 1991; Vainio and Boffetta 1994), which is not the case in MM. In 
lung cancer, regardless of histologic subtype, the incidence has been estimated as a 5-fold 
increased lung cancer risk. Smoking alone has been calculated as about a 10-fold risk, and in 
workers with both exposures, the risk has been estimated at about 50-fold above that for the 
unexposed non-smokers (Selikoff et al. 1968). Wagner et al. reported that exposure / 
inhalation experiments with rats increased incidence of lung cancer in rats with asbestosis 
(Wagner et al. 1973). 
Unlike asbestos-related lung cancer where tobacco has been recognized as a co-carcinogen 
(Selikoff and Greenberg 1991; Vainio and Boffetta 1994), no link between tobacco-exposure 
and MM has been established (Clemmesen and Hjalgrim-Jensen 1981; Muscat and Wynder 
1991). The only mineral other than asbestos that has been suggested to play a role in 
carcinogenisis is erionite, an organic mineral found in volcanic areas in central Turkey (Baris
et al. 1979; Metintas et al. 1999). There are other asbestos-related diseases i.e. asbestosis, 
benign pleural effusions, pleural plaques and airflow obstruction.  
2 MALIGNANT MESOTHELIOMA (MM)  
The  mesothelium,  the  lining  of  the  serosal  cavities  of  pleura,  pericardium  and  peritoneum  
consists of a monolayer of specialized, predominantly flattened, and squamous-like 
mesothelial cells. The mesothelium develops from mesodermal tissue, and mesothelial cells 
provide a protecting barrier against physical damage and invading pathogens. The 
Review of the Literature 
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
16
mesothelial cells secrete surfactants, proteoglycans and glycosaminoglycans to provide a 
smooth, non-adhesive surface which allows movement. Although the exact origin of MM is 
unclear, it is thought to arise from mesothelial cells. Other theories propose that it arises from 
submesothelial cells that differentiate in several directions. The malignant pleural tumors 
mainly comprise of diffuse MM, whereas benign pleural tumors include solitary fibrous 
tumor, well differentiated papillary mesothelioma and adenomatoid tumour (Travis et al.
2004).
The connection of asbestos as an etiological factor in MM was first confirmed in studies of 
asbestos miners from South Africa (Wagner et al. 1960). A high incidence of MM was 
documented among insulation and shipyard workers in the United States (Selikoff et al.
1965; Selikoff and Hammond 1979). In several villages in south-central Turkey, widespread 
incidences of MM and lung cancer have been associated with exposure to abnormally high 
concentrations of naturally occurring mixed airborne fibres, including the zeolite mineral 
erionite and several different kinds of asbestos minerals (Baris et al. 1987; Baris et al. 1981). 
In addition to the industrial use of asbestos, the material can be found in industrial plants 
where previously asbestos was used in the production process, in buildings, and in 
contaminated soils. Exposure to erionite and the MM incidence in Cappadocia (Turkey) has 
been thoroughly investigated since 50 % of the deaths in the villages of Tuzkoy, Karain, and 
‘‘Old’’ Sarihidir are due to MM (Dogan et al. 2006). Their study demonstrated that MM was 
more prevalent in some families than in others, suggesting that certain individuals have a 
genetic predisposition for MM. A genetic predisposition may influence mineral fibre 
carcinogenesis. Glutathione S-transferase mu 1 (GSTM1) null  genotype  and  the  N-
acetyltransferase 2 (NAT2) slow acetylator genotype have been suggested to confer about a 
2-fold increased risk of developing MM (Hirvonen et al. 1995). 
In 2007, 70 new cases of MM were diagnosed in Finland, of which 53 were males and 17 
females (http://cancerregistry.fi). In the US the annual number is about 2500 and 1000 in the 
UK. The global incidence of MM cases continues to rise due to the ubiquitos use of asbestos 
fibres in the past and the long latency period between exposure and appearance of the 
disease. The pleura is the most common site for MM, followed by the peritoneum, 
pericardium and the tunica vaginalis of testes and ovaries.  
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Pediatric MMs are very rare and account for about 2-5 % occurring before the age of 20 
years of all cases diagnosed. Peritoneal MMs have been described (Niggli et  al. 1994), as 
well as pediatric MM as a consequence of Wilm´s tumour in children (Antman et al. 1984; 
Austin et al. 1986). Here, the question of genetic predisposition arises, and it is more difficult 
to link these cases to former asbestos exposure (for a review of pediatric MM see (Fraire et 
al. 1988). Co-factors, such as genetic predisposition (Ascoli et al. 1998; Carbone et al. 2007; 
Dogan et al. 2006) and possibly simian virus 40 (SV40) have been claimed to have a role in 
MM (Carbone and Pass 2006; Kroczynska and Carbone 2006; Pass et al. 2004a). SV40 was 
present in the tumour cells, but not in the normal cells (Bocchetta et al. 2000; Shivapurkar et 
al. 1999).
2.1 Histological classification of MM 
According to the WHO classification 2004, MM can be classified as epithelial (MM-E), 
biphasic (MM-B), and sarcomatoid (MM-S) (Travis et al. 2004). These groups show 
significant differences in their histological and clinical features (see Figure 2). The majority, 
about 50 %, of MMs is of the epithelioid subtype, 10% are sarcomatoid and the rest are 
biphasic. In addition, there are several further subtypes, including desmoplastic (Kannerstein 
1980) and lymphohistiocytoid mesothelioma (Henderson et al. 1988),  with  some  of  these  
subtypes  carrying  a  particularly  adverse  prognosis;  for  example,  MM-S  generally  has  a  
shorter survival than MM-E, and desmoplastic mesotheliomas, as subtype of MM-S, is 
characterized by an even shorter survival compared with MM-E and MM-S without 
desmoplastic features. In addition, deciduoid MM, a rare phenotype of MM-E (Nascimento
et al. 1994), and comprise only 5 % of all diagnosed cases of MM (Shia et al. 2002). MM-E 
tumours usually show well-differentiated tubopapillary structures or solid sheets, with round 
polygonal tumour cells with abundant densely eosinophilic cytoplasm and the rather open 
nuclei show few or no mitoses. MM-S display spindle-shaped or oval morphology, and 
amphophilic cytoplasm, arranged in fasicles or having a random distribution. An aggressive 
subtype of MM-S is desmoplastic MM, which is characterized by dense collagenized tissue 
arranged in a storiform pattern, this being easily confused with benign pleuritis. MM-B 
displays both types of features, with at least 10 % of both components.  
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Well-differentiated papillary mesothelioma is a rare type, and most often evolves from the 
peritoneum in women, but may also arise in both men and women in the visceral and parietal 
pleura. It is considered as benign or with a low malignant potential tumor with a relatively 
good prognosis. This tumour type can sometimes occur within MM, and small biopsies need 
to be evaluated carefully (Burrig et al. 1990; Daya and McCaughey 1990).  
In addition, Klebe et al. (2008), proposed a definition for recognition of heterologous MM, 
and based on its clinical, radiological, histologic, and immunohistochemical characteristics 
they  claimed it  to  be  a  different  entity  from other  MM subtypes  (Klebe et al. 2008). Since 
there is scarce data about heterologous MM and only a few cases with these components 
have been reported (Kiyozuka et al. 1999), it is hard to speculate if there would be a possible 
difference in the outcome of prognosis. 
Figure 2. Histology of MM a) MM-E b) MM-S c) MM-B (personal photographs by Kaisa 
Salmenkivi). All figures are stained by haematoxylin-eosin staining (x 300). 
The cytologic features of MM may include vacuolated cytoplasm; nuclei may be round or 
oval and have coarse, irregular chromatin for MM-E. MM-S does not shed into the pleural 
fluids, but may be seen as clusters or as sarcoma-like spindle cells in aspiration cytology. 
2.2 Molecular genetics and pathology of MM 
Due to the long latency period between asbestos exposure and tumour development, it seems 
probable that multiple and likely diverse genetic changes are required for the malignant 
transformation of mesothelial cells. Several sites of DNA copy number changes have been 
reported, but no specific translocation. In the last decade, the role of genetic polymorphism in 
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the pathogenesis of cancer and other diseases has been an object of research. Even though 
MM has been considered for many years as the paradigm of an environmentally determined 
cancer, a genetic contribution in the etiology has been hypothesized, since not all heavily 
exposed persons develop MM. This consideration, together with reports of MM familial 
clustering (Ascoli et al. 2007; Carbone et al. 2007), suggest a role of genetic susceptibility.  
2.2.1 DNA copy number changes in MM 
The direct  or  indirect  effect  caused  by  asbestos  exposure,  mainly  depends  on  type  of  fibre  
and the time of exposure. Chrysotile is less toxic/harmful than the other fibres, and is cleared 
faster from the lung tissue by mechanisms including fragmentation. In contrast to the other 
fibres, a short exposure time to chrysotile has not been connected with any histopathological 
alteration in lung tissue (Cortez and Machadosantelli 2008).  
Conventional karyotypic and comparative genomics hybridization (CGH) studies, as well as 
high-resolution studies using microarrays have demonstrated that MM samples display 
numerous chromosomal alterations. Some studies have not distinguished between the 
separate subtypes (Balsara et al. 1999; Bjorkqvist et al. 1997; Bjorkqvist et al. 1998; Taguchi
et al. 1993), but most cases reported are of MM-E subtype (Krismann et al. 2002; Taguchi et 
al. 1993). Many regions of chromosomal gains and losses have been reported, and 
losses/deletions are more frequently reported than gains. The accumulation of numerous 
chromosomal deletions/losses in most MMs might suggest a multistep process of 
tumourigenesis, characterized by the loss and/or inactivation of multiple TSGs. 
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Figure 3. Array CGH is able to detect genome-wide copy number changes in tumour 
samples A) gives an overview over all chromosomes (losses are shown in red) B) displays a 
more detailed chromosome view C) detailed gene view of selected area. All pictures are 
taken from the CGH Analytics software (Agilent Technologies, Palo Alto, CA, USA).
Losses have been reported at 1p, 3p, 4q, 6q, 9p, 13q, 14q and 22. Minimal overlapping areas 
can be found, but the exact break points vary and are rather diffuse. Chromosomal gains 
which are less common than losses are reported at sites such as 1q, 5p, 8q, 15q (Bjorkqvist et 
al. 1997; Bjorkqvist et al. 1998; Ivanov et al. 2009; Krismann et al. 2002; Taniguchi et al.
2007).
Gene losses/deletions in MM 
Several oncogenes and TSGs have been hypothesized to play a role in pleural MM 
carcinogenesis (Lechner et al. 1997). The TSGs RASSF1A, NF2, and CDKN2A, as well as the 
growth factors/proto-oncogenes/signaling molecules c-fos, c-jun, EGF, VEGF, c-Met, c-myc,
and fra-1 are important in many malignancies. Since most of the copy number changes are 
losses, including many areas harbouring TSGs, this is probably a central event in MM 
carcinogenesis. Losses at 3p have frequently been reported in MM, and reduced FHIT
expression has been reported as a consequence of exposure to carcinogens such as tobacco 
smoke and asbestos. Reduced FHIT expression was found in MM tumours (Pylkkanen et al.
2004). Another region, 3p21.3 has been linked to asbestos-related lung carcinogenesis 
(Wikman et al. 2007). One of the genes, RASSF1A, encodes a pro-apoptotic tumour 
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suppressor (Matallanas et  al. 2007) and its loss is associated with many cancers including 
MM (Toyooka et  al. 2002).  At  least  two  more  genes  from  the  same  area,  TUSC2 and 
TMEM11, may also be associated with cancer. Forced expression of TUSC2 resulted in 
tumour growth suppression (Ji et  al. 2002). It was found that expression of TUSC2 could
stimulates p53-regulated apoptosis (Deng et al. 2007), and thus both genes might be 
important TSGs.  
The most common loss/deletion is at 9p21, including the tumour suppressors p16INK4a and 
p14ARF (encoded by alternative reading frames of CDKN2A) and p15INK4b (encoded by 
CDKN2B)  (De  Rienzo  and  Testa  2000;  De  Rienzo et al. 2000). These TSGs encode for 
cyclin-dependant kinase (CDK) inhibitor proteins that function in the retinoblastoma (RB) 
pathway regulating the cell cycle during the G1/S phase. Mice deficient for p16INK4a, p14ARF
and p15INK4b are more tumour-prone and develop a broader spectrum of tumours than 
Cdkn2a mutant mice (Krimpenfort et al. 2007). CDKN2A is often homozygously deleted in 
most  MM  tumors  (Cheng et  al. 1993; Cheng et al. 1994; Chiosea et al. 2008; Illei et al.
2003a; Illei et al. 2003b; Ladanyi 2005; Onofre et al. 2008; Xio et al. 1995), as well as other 
cancer types (for a review see Sharpless 2005). CDKN2A was found to be more commonly 
deleted in pleural MM than peritoneal MM, and it was claimed to be a possible marker for 
distinguishing MM from pleural effusions (Chiosea et al. 2008). Other genes at 9p21.3 
include MTAP and CDKN2B,  which  have  been  shown to  be  co-deleted  in  some MM cases  
(Illei et al. 2003b; Ladanyi 2005). Examination of the state of methylation of several cell 
cycle gene promoters in MM has demonstrated that hypermethylation can down-regulate 
CDKN2A expression in 10-20% of MM (Christensen et al. 2008). In an extensive study 
investigating the hypermethylation of cell cycle and progression genes, it was found that the 
methylation status of the genes RASSF1, CDKN2A, CDKN2B, APC, CCND2, and HPPBP1
correlated with the asbestos count in pleural MM (Christensen et  al. 2008). Repeated 
passaging  of  cells  in  tissue  culture,  similar  to  the  process  of  aging,  is  associated  with  the  
induction of TSG silencing by promoter methylation (Baylin 2002) and could potentially be 
one mechanism evoked by asbestos. The deletion of CDKN2A is a possible negative 
prognostic factor in MM (Ivanov et al. 2009; Lopez-Rios et al. 2006). 
Loss  of  17p  is  a  common  event  in  MM,  with  TP53 localized on 17p13.1, but TP53 is 
reported not to be included in the critical region (Ivanov et al. 2009). In MM, the deletion of 
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CDKN2A interrupts both the p53 and pRb pathways, which are very important in the 
development of cancer. This is important since TP53 mutations have been detected in many 
tumours, but they are only observed occasionally in MM. Some studies have demonstrated 
that TP53 (Papp et al. 2001), as well as the Rb family of genes (De Luca et al. 1997) remain 
genetically intact in MM tumours.  
Chromosome 19 is the most gene dense chromosome, and 19p13.1p13.3 has been reported to 
be altered in asbestos-related lung cancer (Nymark et al. 2008; Wikman et al. 2007). Allelic 
balance of the chromosomal region 19p13.3p13.1 was further assessed using 5–19 
microsatellite markers with approximate coverage of 22 Mbp (Wikman et al. 2007). In 
adenocarcinomas, allelic imbalance in 19p appeared to occur independently of the asbestos 
exposure. In MM, aberrations in chromosome 19 have been detected in ~55 % of the tested 
samples, and 11 genes at 19p13 were claimed to be lost in MM (Ivanov et al. 2009).  
The  TSG  neurofibromin  2  (NF2) is located at 22q12.2, and loss of chromosome 22 was 
shown to be a recurrent cytogenetic abnormality in ~50 % of the MM cases (Pylkkanen et al.
2002). The NF2 encodes merlin, which plays a role in the connection between the 
cytoskeleton and components of the plasmatic membrane. Merlin has also been suggested to 
be an inhibitor of the Ras-ERK pathway (Lim et al. 2003) by exhibiting tumour suppressor 
function and inhibiting PAK induced cyclin D1 expression (Xiao et al. 2005). Ivanov et al.
(2009) reported loss of another gene at 22q12.2, OSM that possesses a growth suppressor 
property and co-deletion of this gene with NF2 might be advantageous for tumour 
progression (Ivanov et al. 2009).
Similarities between human and mice asbestos-related TSG patterns, in murine and human 
mesothelial cell lines have indicated similar losses of TSG functions (Lecomte et al. 2005).
Oncogenes involved in MM carcinogenesis 
MM  has  an  unusual  molecular  pathology  with  loss  of  TSGs  being  more  common  than  
activation of oncogenes (Metcalf et al. 1992; Mor et al. 1997), although SV40 T antigen has 
been proposed to potentially inactivate p53 and pRb function (Carbone et al. 1997; De Luca 
et al. 1997; Mutti et al. 1998). KRAS mutations are common in human cancers, but do not 
appear to be widely involved in human MM, although one study did propose that the Ras 
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pathway could be affected in human MM cell lines (Patel et al. 2007). Since the molecular 
profile of patients who are never-smokers differs, from those who are smokers/former 
smokers, this subset of tumours appears to have a different mechanism of carcinogenesis. 
EGFR mutations are common in non-smokers, whereas KRAS, TP53 transversion mutations, 
and p16 promoter hypermethylation are more frequent in smokers (for a review see (Sun et 
al. 2007). In the same way, separate molecular profiles for asbestos-related lung cancer might 
emerge.  
High-level gain at 1p32.1 including amplification of JUN proto-oncogene has been reported 
in MM (Taniguchi et al. 2007). Research in rat pleural mesothelial cells have indicated that 
asbestos can induce expression of JUN and/or FOS (Heintz et al. 1993). Taniguchi et al.
(2007) further investigated FOS expression and found that it was mostly up-regulated 
simultaneously with JUN.
2.3 Diagnoses and prognosis of MM patients 
In MM diagnostics, chest radiography, chest computed tomography, magnetic resonance 
imaging  of  the  chest  and  IHC  panels  are  the  most  widely  used  tools.  However,  it  may  be  
difficult to make an early diagnosis of MM using the currently available diagnostic imaging 
techniques and it would be beneficial to have identification of tumour markers and a method 
for early diagnosis using these markers. 
Less than 50% of MM patients survive over one year after diagnosis. The diagnosis of MM is 
dependent on a consideration of clinical and radiological findings in combination with 
pleural fluid cytopathology and pleural biopsy. When thoracoscopy is used to obtain 
sufficient tissue, the histological differential diagnosis may still prove difficult. It includes 
distinguishing well-differentiated MM-E from reactive mesothelial proliferation, sarcomatoid 
or desmoplastic MM from reactive pleural fibrosis, and MM-E from metastatic or 
pseudomesotheliomatous carcinoma, usually adenocarcinoma (Dejmek 1996; Grove et al.
1994; Kortsik et al. 1995; Sheibani et al. 1992; Wick et al. 1990). IHC has proved most 
valuable in diagnoses, and despite many antibodies showing potential, no antibody shows 
absolute specificity or sensitivity for either tumour type (King and Hasleton 2001). 
Therefore, the IHC panel of antibodies (see Table 2) is a valuable diagnostic approach for 
achieving optimal sensitivity and specificity. Abutaily et al. (2002) evaluated a range of 
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antibodies for their specificities and sensitivities in MM and adenocarcinoma, and found that 
E-cadherin was 100% sensitive for adenocarcinoma and TTF-1 100% specific for MM. 
These  two antibodies  and  the  addition  of  a  secondary  antibody panel  consisting  of  BerEP4 
and LeuM1 and antibodies directed against carcinoembryonic antigen, calretinin, cytokeratin 
(CK) 5/6, thrombomodulin, and N-cadherin were enough to achieve a differential diagnosis 
(Abutaily et al. 2002). See Table 2 for antibodies used in differential diagnostics of MM and 
metastatic pulmonary/pleural adenocarcinoma. 
In  recent  years  advances  have  occurred  in  the  management  of  patients,  including  more  
accurate staging. The recommended classification of staging of MM for clinical use is that 
propsed by the International Mesothelioma Interest Group (IMIG) (Rusch 1995), based on 
the TNM system of lung cancer. Although staging is difficult, and has little use for disease 
management, it has surgical implications, and parallels prognosis. To date there is no specific 
molecular marker that can predict prognosis, although soluble mesothelin related peptides 
(SMPR) have been associated with favorable prognosis in MM-E (Roe et al. 2008). Today 
better prognosis has been suggested to correlate with epithelioid subtype, younger age, and 
no asbestos exposure history, but specific markers that could predict prognosis still need to 
be found/evaluated before they can be useful in the clinic (Christensen et al. 2008; Flores et
al. 2007). 
Table 2. IHC panel for MM and metastatic pleural adenocarcinoma (see (Marchevsky 2008; 
Ordonez 2007) for review). 
Cancer /Marker Positive  
immunoreactivity 
Sporadic  
immunoreactivity 
Negative
immunoreactivity 
MM / 
mesothelial 
markers 
CK 5/6, Pan-kreatin, 
calretinin, WT-1, 
thrombo-modulin, 
HBME-1 
MOC-31, B72.3, CEA,  
LeuM1, BerEP4, TTF-1 
Adenocarcinoma 
/Epithelial 
markers 
CK7, AE1/AE3,  
CEA, TTF-1, EMA, 
HMFG-2, MOC-31 
LeuM1, BerEP4,  
B72.3, Vimentin 
CK5/CK6, CK20 
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Cyclo-oxygenase 2 (COX-2) is involved in tumour proliferation, increased angiogenesis, and 
tumour invasiveness (Tsujii et al. 1997; Uefuji et  al. 2000), and has been implicated as a 
poor prognostic factor in MM (Edwards et al. 2002). COX-2 is linked to activation of EGFR, 
and can be induced by HGF and PDGF, which are associated with MM pathogenesis 
(Langerak et al. 1996). EGFR is over-expressed in many epithelial tumours including MM, 
and activation of the receptor can evoke cell proliferation, survival and transformation. A 
strong expression of EGFR has a favourable outcome in MM patients (Edwards et al. 2006). 
Although a functional loss of Rb is not common in MM, the loss of the cyclin-dependent 
kinase (CDK) inhibitor p16/ INK4a, is a very central event in MM, and has been correlated 
with a worse prognosis (Ivanov et al. 2009; Lopez-Rios et al. 2006). Expression of another 
CDK inhibitor, p27(kip1), has been correlated with longer survival (Bongiovanni et al.
2001). Together with the proliferation marker Ki-67, increased expression of p27(kip1) 
possesses a sensitivity and specificity of 100 % and is a predictive marker for favourable 
survival (Bongiovanni et al. 2001). Other prognostic makers studied have been studied e.g. 
syndecan-1 (Kumar-Singh et al. 1998)  and thrombospondin-1 (Ohta et al. 1999). 
Identification of new, more specific and reliable prognostic markers would help in 
counselling and management of MM patients. 
It is often a diagnostic challenge to distinguish between MM, adenocarcinoma and reactive 
mesothelial proliferation in cytologic specimens. Many techniques, such as cellblock 
preparation, histochemical, IHC and ultrastructural analysis have been used to try to resolve 
these diagnostic problems. Reactive mesothelial cells typically form smaller, less complex 
groups than those of MM, which show larger, more complex aggregates. When one tries to 
distinguish MM from adeonocarcinoma, three major features have to be taken into 
consideration i.e. the presence of giant atypical mesothelial cells, acinar structures and 
nuclear pleomorphism (Cakir et al. 2008).
2.4 MM therapy options, and treatment resistance 
MM is difficult to diagnose at an early stage and practically all available single modality 
treatment options (surgery, radiotherapy, chemotherapy, immunotherapy, gene therapy) are 
ineffective. Progress in this field is evolving, and several new drugs have been developed, 
and trials are in progress to evaluate whether earlier treatment (including combined surgery 
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and radio/chemotherapy), as well as new combined chemotherapy options, which might be 
useful in improving survival or even cure the disease. Approximately 85-90 % of the patients 
with pleural MMs present with unresectable disease. For the majority of the MM patients not 
eligble for surgery, options include chemotherapy and other palliative treatment modalities 
(Fennell et al. 2008). 
Trials including comparing chemotherapy with best supporting care are underway (Favaretto 
2005) as well new combined chemotherapy options. Whereas cisplatin is found to be the 
most active single drug (Berghmans et al. 2002), combination therapy has been linked with 
higher response rate, but unfortunately not achieving longer survival times. Other cytotoxic 
agents have been evaluated e.g. gemcitabine, vinorelbine, and antifolates such as pemetrexed 
and raltitrexed. Supplements with folic acid and vitamin B12 have reduced toxicity 
significantly. The patients unfit for cisplatin therapy were treated with carboplatin, but the 
survival time remained the same (Hughes et al. 2002). The use of pemetrexed in combination 
with other agents may have a beneficial effect, particularly in early stage of disease, and 
therapy excluding premetex seemed to have no benefit in extending survival in MM patients 
(Muers et al. 2008). 
As new effective agents are developed for initial treatment, several classical cytotoxic drugs 
and many novel agents are being evaluated in second-line settings. These include drugs 
targeted against the EGFR, platelet derived growth factor (PDGFR), vascular endothelial 
growth factor (VEGFR), histone deacetylase, the proteasome, and mesothelin (Tsao et al.
2009).
Clinical trials including autologous vaccination with mesothelioma cells, angiogenesis 
inhibitors, bevacizumab and thalidomide, the EGF and PDGF receptor tyrosine kinase 
inhibitors  (Gleevec),  respectively  and  more  active  cytotoxic  combinations  of  chemo-  and  
immunotherapeutic agents have been conducted. It has been proposed that a successful 
treatment will almost certainly involve a combination of approaches (Nowak et al. 2002).
The receptor tyrosine kinase MET receptor, is proposed in a variety of cancers, including 
lung cancer and MM. Over-expression or mutation of this receptor or its ligand hepatocyte 
growth factor (HGF) promotes cell growth, survival, angiogenesis, and metastasis. In a study 
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focusing on c-Met receptor tyrosine kinases in pleural MM cell lines (Jagadeeswaran et al.
2006), it was found that serum circulating HGF was twice as high in MM patients as in
healthy controls. There was a differential growth response and activation of AKT and 
extracellular signal–regulated kinase 1/2 in response to HGF in the various cell lines. It was 
suggested that targeting the HGF/c-Met pathway could be of therapeutic importance. Serum 
HGF levels can be higher in MM patients as compared with control subjects, thus potentially 
serving as a biomarker in pleural MM (Jagadeeswaran et al. 2006). 
Proteasome inhibitors for restricting signaling pathways in MM, such as the FDA approved 
proteasome inhibitor bortezomib could wipe out NF-B activity in MM (Sartore-Bianchi et 
al. 2007). Bortezomib is highly cytotoxic to pleural MM cells and induced both G(1)/S  and 
G(2)/M cell cycle arrest. Apoptosis, induced by this proteasome inhibitor increased in a 
concentration- and time-dependent manner in MM cell lines (Gordon et al. 2008). 
Vector systems (adenovirus and vaccinia virus) and transgenes (herpes simplex virus 
thymidine kinase) trials have been conducted for MM, but yet without any significant clinical 
breakthrough (van der Most et al. 2006). Methods such as gene therapy targeting promoter 
region, induction of apoptosis by targeting pro-apoptotic genes (Mohiuddin et al. 2001; 
Pataer et al. 2001) or cell lysis by replicative oncolytic adenovirus (Bischoff et al. 1996), 
have been tested. A study examining different promoter systems specifically targeting MM 
cells and abnormal cells, found that a CREBBP/EP300 inhibitory protein 1 gene promoter, 
expressing genes to induce apoptosis was the most specific way to target the cancer cells 
(Fukazawa et al. 2008).
Although no curative therapy has been found, progress has been made in recent years. 
Randomized trials have confirmed that combining antifolates with platinum-based therapy 
leads to an improvement in survival. During the past 5 years, advances have been made in the 
first-line therapy of inoperable pleural MM. Clinical prognostic scores provide tools for 
identification of patients likely to do better or worse following diagnosis of pleural MM; 
however, good predictive markers that can reliably identify chemoresistant subgroups still 
need to be translated into routine clinical practice. Translational research is considered a 
standard component of the design process of clinical trials, and the possibilities of using 
biomarkers to predict, detect, and monitor disease make personalized medicine more real.  
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3 IDIOPATHIC PULMONARY FIBROSIS (IPF) 
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology, uncertain pathogenesis 
and to date there are no effective therapies available. IPF is one of seven different 
clinocopathological entities of idiopathic interstitial pneumonias. The classification is based 
on the international consensus statement by the American Thoracic Society (ATS) and 
European Respiratory Society (ERS) (ATS/ERS 2002). IPF is the term used for clinical 
diagnosis, whereas the typical histopathological pattern seen in surgical biopsies is termed 
usual interstitial pneumonia (UIP). It is a chronic progressive interstitial lung disease and 
excessive deposition of extracellular matrix (ECM) leads to irreversible scarring of lung 
tissue (see Figure 4). IPF is characterized by a reduction in gas exchange and loss of lung 
volume. Cigarette smoking is to some extent associated with IPF development and prognosis. 
The correlation between smoking history (20–40 pack-years) and risk for IPF produced an 
odds ratio of 2.3 for smokers (Baumgartner et  al. 1997). The prevalence is higher in men 
than women, and familial cohorts of IPF have been described, but sporadic cases constitute 
the majority of the disease. Clinical features of familial IPF are not distinguishable from 
those of the sporadic form, with the expectation of an earlier age of onset (Garcia and Raghu 
2004). No single gene defects have been identified, though polymorphisms of hTERT and 
hTR in a cohort of patients with familial IPF have been described (Armanios et  al. 2007). 
These genes are involved in regulation of telomere length and thereby play an important role 
in controlling cell death and aging.  
IPF is probably multi-factorial, and evidence is accumulating to implicate viruses, such as 
hepatitis C virus, adenovirus, human cytomegalovirus and, in particular, the Epstein-Barr 
gamma herpes virus, as co-factors (either as initiating or exacerbating agents). Stress, drug 
exposures or immunodeficiency may be responsible for viral reactivation in some patients, 
but not others (for a review see Vannella and Moore 2008). 
Asbestos induced pulmonary fibrosis is caused by inhalation of asbestos fibres, and is 
defined as a type of diffuse bilateral interstitial pulmonary fibrosis. The disease has a dose-
response relationship; thereby a risk group can be identified when exposure exceeds a certain 
threshold. The fibrosis seen in asbestosis is primarily collagen instead of granulation tissue, 
such as occurs in several other interstitial lung diseases (e.g. sarcoidosis) and acute lung 
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injuries. The radiologic and distribution mimics that of usual interstitial pneumonia (UIP), 
with  clinical  presentation  of  IPF  in  that  it  is  worse  in  the  lower  lung  zones  and  periphery  
(Leslie 2005).
Asbestosis can not be diagnosed from cytology, but requires a biopsy and histologic 
evaluation. The histological features display the characteristic patterns of diffuse interstitial 
fibrosis and the presence of asbestos. Typical histopathological features in UIP include 
fibroblastic foci lesions that represent areas of fibrogenesis. Fibroblastic foci have been found 
to occur also in pulmonary asbestosis. Asbestosis is often diagnosed along with other 
asbestos-related diseases - i.e. MM and/or lung cancer. Histologically, the term asbestosis 
refers  to  interstitial  fibrosis  caused  and  diagnosed  by  the  evidence  of  asbestos  fibres  in  the  
lung (ATS, 2004). In experimental models of lung fibrosis, asbestos exposure leads to a 
histological presentation of fibrosis that has major similarities with UIP. The histological 
finding typically shows relatively weak inflammation and the presence of fibroblastic foci in 
the lesions correlates with the prognosis of IPF (ATS, 2001). There is a statistical association 
between asbestos-related diseases and cancer, but the majority of the patients with non-
malignant asbestos-evoked disease do not develop cancer (ATS, 2004). 
3.1 Pathogenesis of pulmonary fibrosis 
The pathogenesis and histopathology of asbestosis resemble that of UIP. Genes contributing 
to the development of asbestosis and asbestos-related cancer have been described, as 
reviewed in (Shukla et  al. 2003b). The pathogenetic mechanisms are incompletely 
understood. Though it has been suggested that injury occurs to the alveolar epithelium and is 
followed by a burst of pro-inflammatory and fibroproliferative mediators that triggers 
responses associated with normal tissue repair. The damage includes loss of type I alveolar 
epithelial cells followed by hyperplastic expansion of type II cells (Adamson et al. 1988); 
inflammatory cell infiltration (Ward and Hunninghake 1998); induction of pro-inflammatory 
cytokines, such as TNF- (Strieter et al. 2007); induction of fibroblast growth factors, 
(Bonner 2004); induction of differentiation molecules, such as TGF- (Gauldie et al. 2007); 
an altered fibroblast phenotype characterized by exuberant proliferation and the transition to 
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-smooth muscle actin-positive myofibroblasts (Phan 2008); and excessive deposition of 
ECM proteins (Kuhn and McDonald 1991); and diminished activation of plasminogen and 
altered coagulation cascades (Laurent et al. 2008).
Due  to  some  still  unknown  reasons,  repair  processes  can  never  resolve  the  damage  with  
progressive fibrosis as a consequence. The origin of pathological fibroblast foci in IPF/UIP 
could be due to differentiation of resident fibroblasts, recruitment of circulating fibroblast 
precursors and/or transdifferentiation of epithelial cells into pathological fibroblast 
phenotypes. Epithelial-to-mesenchymal transition (EMT) is a characteristic feature of cells 
undergoing proliferation. In pulmonary research, epithelial and mesenchymal markers in 
histologic specimens obtained from IPF patients are co-expressed, which points to a role in 
pulmonary fibrosis (Willis et al. 2005). 
There  are  two  theories  of  the  pathogenesis  of  IPF/UIP,  one  stresses  the  importance  of  
inflammation as the trigger to fibrosis, and the other that fibrosis arises as a consequence of 
chronic epithelial injury and failure of repair due to aberrant EMT. Maher et al. (2007) 
proposed the involvement of multiple pathway mechanisms, since IPF/UIP is a very complex 
disease, i.e. injury activates many inflammatory, cell signaling and repair pathways. 
Abnormalities in each of these key pathways could vary between affected individuals, 
accounting for the wide range of phenotypes observed in IPF (Maher et al. 2007). 
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Figure 4. Pathogenesis of IPF (modified from Barnes 2008). 
3.1.1 Transforming growth factor– (TGF-)
Transforming growth factor– (TGF-), a multifunctional cytokine, can be activated by ROS 
derived from chrysotile and crocidolite asbestos. TGF- exists in three mammalian isoforms, 
TGF-1, TGF-2 and TGF-3, and is produced in an inactive form and stored in a high 
concentration in the ECM. Before they can become biologically effective, these factors have 
to  be  converted  into  the  active  form  after  which  they  can  bind  to  their  receptor.  TGF- is  
chemotactic for fibroblasts, and it stimulates fibroblast proliferation, inhibition of expression 
of metalloprotease genes, and increases the synthesis of a number of ECM proteins including 
collagens. Whereas prolonged inflammation can lead to tissue destruction and loss of 
function, increased TGF- activity can lead to scar formation and loss of function (Roberts et 
al. 1986). The absence of inflammation can prevent the critical actions of inflammatory cells 
in killing invading micro-organisms and/or removing potentially  toxic  debris.  Activation  of  
latent TGF- is an important mechanism for regulating TGF- function (Annes et al. 2003).  
Review of the Literature 
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
32
TGF- has been described in the induction of fibrosis in various tissues including the lung 
(Sime and O'Reilly 2001). TGF- is  up-regulated  in  lungs  of  patients  with  IPF,  and  
expression of  active  TGF- in  lungs  of  rats  evokes  a  dramatic  fibrotic response, and the 
inability to respond to TGF- affords protection from bleomycin-induced fibrosis. TGF- is a 
major inducer of EMT in development, carcinogenesis, and fibrosis with different isoforms 
mediating various events (Nawshad et al. 2005). 
GATA factors have been reported to co-operate with TGF- signaling in the immune system 
and the heart (Blokzijl et al. 2002; Brown et  al. 2004),  also  interpreted  as  a  role  for  these  
transcription factors in disease. GATA-6 is one of the six members of the mammalian GATA 
family of transcriptional regulators, each having two zinc finger domains and which bind to 
the common DNA sequence element (A/T)GATA(A/G) (Molkentin 2000). GATA factors 1–
3 are expressed mainly in hematopoietic lineages, while GATA factors 4 – 6 are expressed in 
various tissues derived from mesoderm and endoderm, including the heart, liver, lung, gut, 
ovary and testis, where they function in cell lineage specification (Molkentin 2000; Patient 
and McGhee 2002). Recent studies have indicated that GATA-6 can be up-regulated in 
various malignancies (Fu et al. 2008b; Guo et al. 2004a; Kiiveri et al. 1999; Siltanen et al.
2003).
3.1.2 Bone morphogenetic proteins (BMPs) and gremlin 
Bone morphogenetic proteins (BMPs) are members of the TGF- superfamily. The binding 
of BMPs to BMP receptors on the cell surface leads to activation of the receptor kinase 
activity, which phosphorylates Smad1/5/8. Smad1, 5, or 8, with Smad4, forms a complex, 
which is translocated to the nucleus, where it binds to a consensus DNA sequence to regulate 
the transcription of BMP target genes. BMPs transduce their signal through receptor-
mediated phosphorylation of cytoplasmic SMAD proteins. Once phosphorylated, SMADs are 
able to enter the nucleus and regulate gene transcription by binding to specific DNA 
sequences in their target genes (for a review see Wrana 2000). 
Gremlin, an antagonist of BMP-7 with a vital role in normal development (Capdevila et al.
1999; Merino et al. 1999; Michos et al. 2004) is over-expressed in many adult pathological 
processes, such as lung fibrosis (Koli et al. 2006) and in stromal cells in several different 
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malignancies (Sneddon et al. 2006). It has been suggested that gremlin could participate in 
EMT, acting as a downstream mediator of TGF-. Gremlin expression was co-localized with 
TGF-, evidence that gremlin indeed could be a downstream mediator of TGF-, either 
acting as an inhibitory protein for BMP-7 creating a profibrotic positive loop or directly by 
promoting the trans-differentiation of epithelial cells. Gremlin may have a role as a mediator 
of EMT and fibrosis. Gremlin has been identified in human pathologies that undergo fibrosis, 
such as IPF (Koli et al. 2006) and liver fibrosis (Boers et al. 2006), suggesting that gremlin 
may represent a potential therapeutic target.  
Gremlin is also selectively up-regulated in the murine lung in response to hypoxia.
Expression of gremlin protein in the murine lung in vivo was markedly increased by hypoxia, 
and this has also been demonstrated in lung tissue from patients with idiopathic pulmonary 
hypertension (Costello et al. 2008). 
The balance between TGF- and BMPs in lung tissue seems to play an important role as 
regulators of lung fibrogenesis; hence it could be a therapeutic target, after being investigated 
further. 
Alveolar epithelial cells
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Epithelial injury
Circulating 
fibrocytes
Adventitial
 fibrocytes
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Regeneration
Gremlin
Growth inhibition
Pulmonary mesenchyme
Figure 5. Schematic figure of the potential functional role of BMPs and gremlin in IPF 
(modified from Koli et al. 2006). TGF- is induced at an early stage and recruits and 
activates fibroblasts to the sites of injury. Pulmonary myofibroblasts persist in fibrotic lesions 
and express the BMP-antagonist gremlin. 
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3.2 Diagnosis and prognosis of lung fibrosis 
The diagnosis of IPF entails clinical, radiological and pathological correlations and a definite 
diagnosis can only be made after a surgical biopsy, (ATS/ERS 2002). IPF is a progressive, 
ultimately fatal disorder. Patients usually experience shortness of breath 6 months prior to 
diagnosis. Pulmonary function tests reveal restriction with reduced vital capacity, usually 
followed by an increased ratio of forced expiratory volume in one second/forced vital 
capacity and reduced diffusing capacity for carbon monoxide (Egan et  al. 2005). High-
resolution computed tomography (HRTC) has proven to be an accurate and sensitive 
diagnostic tool for IPF (Lynch et al. 2005). HRTC visualizes thin tissue sections and 
abnormalities in the lung parenchyma can be identified. In most cases the definitive 
diagnoses is made through lung biopsies, which should be taken from different lobes of the 
lung, since UIP and non-specific interstitial pneumonia (NSIP) can co-exist in the same lungs 
of the patient (Monaghan et al. 2004). Diagnosis not made from biopsies include cases were 
the exclusion of other diseases can be made, and there are the typical features at HRT, as 
evidenced in bronchoalveolar lavage (reviewed in Fishbein 2005).  
The prognosis is poor, median survival is estimated to be 2.8 - 4.2 years after diagnosis and 
there is no effective therapy. Poor prognostic factors are smoking history, increased age, 
male sex and UIP histology (King and Hasleton 2001). The accumulation of fibroblastic foci 
has been associated with higher mortality (Nicholson et al. 2002).  The  role  of  lung  
transplantation(s) for IPF patients indicated worse prognosis, but better prognosis for patients 
receiving two lungs, therefore the authors of the study suggested a double lung transplant, but 
emphasized that the results need to be confirmed in a randomized trial, due to the scarcity of 
samples (Mason et al. 2007). After lung transplantation, approximately 40 % of the patients 
are still alive after 5 years (Thabut et al. 2003). IPF is a progressive disease, and current 
treatment modalities are limited, mostly unsuccessful, and limited to anti-inflammatory and 
immunosuppressive drugs. The only drug exhibiting some effect on lung function 
deterioration is N-acetylcysteine (Demedts et  al. 2005) perhaps emphasizing the role of 
oxidants in IPF progression. 
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4 HIGH-RESOLUTION PROFILING METHODS IN FINDING MARKERS FOR 
DETECTION OF DISEASES 
High-throughput genomics, transcriptomics and proteomics profiling revolutionized ways of 
finding novel cancer related biomarkers. Genomic and expression profiling allow 
simultaneous examination of hundreds of thousands of genes and present opportunities to 
obtain molecular signatures in clinical samples. Developing technologies will most probably 
reduce costs and diagnosis times in the future, making sequence analyses of tumours and
human genomes, more common. Today microarrays are being used in many diagnostic 
laboratories along with other methods.  
4.1 Microarray platforms  
Conventional comparative genomic hybridization (CGH) for studies on copy number 
changes involved in carcinogenesis was introduced by Kallioniemi et al. (1992), and since 
then high-resolution methods for revealing diseases associated DNA copy number changes 
have evolved rapidly.  
Genome-wide array CGH profiling allows a deeper insight into the biology of a variety of 
tumours. Array CGH can be performed on three types of slides containing oligos, cDNA or 
bacterial artificial chromosomes (BACs). The array methodology using inserts from genomic 
sequences was first introduced using BAC clones (Pinkel et al. 1998), quickly followed by 
cDNA clone containing arrays (Pollack et al. 1999). Subsequently, oligonucleotide based 
arrays (Lucito et al. 2003) have gained increasing interest due to their high resolution. The 
methodolgy is expanding at a brekneck speed from a tiling resolution BAC array (Ishkanian
et al. 2004) to oligonucletide arrays containing hundreds of thousand of probes. Massively 
parallel sequencing, a high-throughput method for detection of genes, not requiring any prior 
knowledge of the gene sequences, is already in wide research use (for a review on platforms 
in use, see Voelkerding et al. 2009).
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Gene copy number changes are presumed to be an early event, and to “drive” the onset and 
growth of a tumour (Mitelman et al. 2004). Once aneuploidy occurs, additional chromosomal 
rearrangements are likely to take place. By the time of diagnoses, there have been many cell 
cycles and what is being measured is not only causal and progressive copy number changes 
but also the passage alterations. As a result, tumour copy number changes profiles probably 
harbor both tumour specific characteristics as well as random aberrations. 
The estimated number of human protein coding genes is currently 21 343 
(http://www.ensembl.org/Homo_sapiens/index.html, accessed 26th March 2009). This 
number is still expected to change, with the number of proteins expected to be about 50 times 
higher due to alternative splicing of mRNA and posttranslational modifications. Gene 
expression arrays, as well as other technologies, including microRNA, epigenetic, 
metabolomic and proteomic analysis have wide and varied applications in biomedical 
research, and include classification of tumours into biological and diagnostic subgroups, 
identification of clinical associations such as prognosis, response to treatment and disease 
progression, as well as helping in identification of novel biomarkers. 
Microarray databases can provide additional information on the expression of candidate 
biomarkers across various tissues, and disease states. Already publicly available information, 
quantitative measures of tissue-specific gene specificity can be used to aid in candidate 
biomarker selection. In the future, these rapidly evolving sequencing methods, may partly 
replace some microarray applications (Wold and Myers 2008). Integration of data from 
genome-wide tools, such as protein or lysate arrays could reveal novel as well as more 
personalized approaches and biomarkers.
4.2 Asbestos associated signatures 
MM is diagnosed at a very late stage, and since usually no effective cure is available, the 
need of biomarkers for early detection of the disease is of high importance. Lately 
independent gene expression panels have been introduced, and these were able to predict 
treatment-related patient outcome in MM independent of the histologic subtype of the tumour 
(Gordon et al. 2003; Pass et al. 2004b). Gordon et al. (2003) used four genes in a three-ratio 
test, suggesting that the use of gene expression ratios would predict outcome in cancer
patients. In a subsequent study Pass et al. (2004b) described a set of 27 genes that they 
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claimed distinguished good-risk and poor-risk surgically treated MM patients. The classifier-
predicted good-risk group had a significantly longer survival and significantly longer time to 
progression than the poor-risk group. 
Currently considerable interest has been focussed on osteopontin and soluble mesothelin 
related protein (SMRP) (Beyer et al. 2007; Di Serio et al. 2007). MESOMARK® (Fujirebio 
Diagnostics, Malvern, PA, USA), an enzyme linked immunoassay (ELISA) has been 
developed to screen persons with a history of asbestos exposure who have a potential risk of 
developing asbestos-related disease (Beyer et  al. 2007). The test has been developed in 
intention to be able to screen for patients with known history of exposure or early signs of 
disease. Osteopontin and SMPRs could be promising biomarkers for early detection and 
diagnosis of several malignancies including MM (Beyer et  al. 2007;  Di  Serio et al. 2007; 
Pass et al. 2005; Robinson et al. 2003; Scherpereel et al. 2006). SMRP was increased in 52% 
and 5% of pleural MM patients and asbestos-exposed individuals, respectively, and the 
elevated levels of SMRP correlated with the epithelioid type, rather than the sarcomatoid 
type of MM (Beyer et al. 2007; Robinson et al. 2003; Scherpereel et al. 2006). Since the test 
entered the market, several groups have evaluated how useful it is in screening for early signs 
of disease (Creaney et al. 2007; Cristaudo et al. 2007; Park et al. 2008). Park et al. (2008) 
did an extensive study including 538 subjects that had a history of asbestos exposure and 
divided into groups depending on asbestos-related disease or still healthy. The study found 
the use of SMRP in detection of asbestos cancer not to be useful in MM screening, due to the 
high false-positive rate (Park et al. 2008). Other markers are osteopontin and megakaryocyte 
potentiating factor that appear to be promising are still subject to some limitations. 
Osteopontin lacks specificity for MM, while both SMPR and megakaryocyte potentiating 
factor lack sensitivity for detecting non-epithelioid subtypes. Results from molecular 
profiling are still too preliminary to be brought into daily clinical practice. 
A combination  of  SMRPs with  the  8OHdG DNA adducts  and  VEGF could  also  benefit  in  
distinguishing the asbestos-exposed subjects from subjects affected by MM and control 
subjects, suggesting that it may be a potential diagnostic indicator for patients at early stages 
of MM (Amati et al. 2008b). The risk for MM was studied through the assessment of the pre-
mutagenic lesion 8OHdG, the pro-inflammatory cytokine IL-6, the angiogenic mediators 
PDGFB,  HGF,  bFGF,  VEGF  and  the  tumour  biomarker  SMRPs  in  relation  to  asbestos  
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exposure-dose (Amati et al. 2008a). The positive correlation between angiogenic plasma 
growth factors and SMRPs indicates that their combination may be useful in screening 
persons with a long asbestos history, pleural plaques and fibrosis, so that asbestos-related 
diseases could be diagnosed earlier.
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II PRESENT STUDY 
1 AIMS OF THE STUDY 
The aims of the study were to screen for molecular and genetic changes of asbestos-caused 
diseases, as well as to further investigate specific signaling pathways. In summary 
1. To elucidate asbestos-related gene expression changes in three human lung cell lines 
exposed to asbestos  
2. To identify specific DNA copy number changes characteristic for MM 
3.  To assess the role of gremlin and its regulation of BMP signaling in pulmonary 
fibrosis 
4. To study GATA-6 transcription factor and its significance in MM and metastatic 
pleural adenocarcinoma  
Materials and Methods 
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
40
2 MATERIALS 
The overview of material and methods used in this thesis is presented in Table 3.  
Table 3. Materials and methods used in this project 
Material Study
Human lung cell lines: A549, Beas-2B I
Human mesothelial and MM cell lines: MeT-5A, M14K, M38K I, IV 
26 Fresh-frozen MM samples II
63 Paraffin-embedded MM samples II, IV 
36 Paraffin-embedded adenocarcinoma samples IV
IPF/UIP and asbestosis patients III
Mice lung tissue III
Methods Study
Cell culture and exposure experiments I, III, IV 
RNA extraction I, III 
DNA extraction II
Agilent Bioanalyzer I
Expression profiling / Affymetrix microarray I
DNA copy number profiling / Agilent´s oligonucleotide platform II
Microarray analysis I, II 
Real-time quantitative PCR III
IHC and ICC III, IV 
Asbestos induced pulmonary fibrosis in mice III
2.1 Materials 
2.1.1 Cell lines (I, III, IV) 
Commercial cell lines and cell lines derived from tumour samples were used. The cell line 
series exposed to asbestos contained human lung adenocarcinoma epithelial cell line A549 
cell line, bronchial epithelial cell line Beas-2B, and human mesothelial cell line MeT-5A. 
These are all commercial cell lines and SV40-transformed. MM cell lines derived from two 
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tumour samples were named M14K and M38K, of which M14K was derived from a patient 
with MM-E and M38K from a patient with MM-B (Pelin-Enlund et al. 1990). 
2.1.2 Lung and pleural specimens (II, III, IV) 
For the array CGH study (II), fresh-frozen and formaldehyde-fixed paraffin-embedded 
tissues were collected at the Department of Pathology/Helsinki University Central Hospital, 
Archives of the Finnish Mesothelioma panel and London Royal Brompton Hospital, London, 
UK. Diagnosis was confirmed based on histological characteristics and 
immunohistochemical (IHC) data. Fifteen epithelioid, eight sarcomatoid, and three biphasic 
fresh-frozen MM cases were obtained. The tumour content was approximated by 
hematoxylin and eosin staining to contain > 50 % of tumour cells.  
For the IHC study a tissue microarray (TMA) was used (IV). Paraffin-embedded tissue was 
collected from Helsinki University Central Hospital from years 1995-2005 and from Oulu 
University Central Hospital between years 1978-2004. Paraffin-embedded tissue was used 
for array CGH and for ICH studies.  
IPF/UIP  and  asbestosis  patient  samples  as  well  as  control  biopsies  were  obtained  from  
Helsinki University Central Hospital. The control samples were obtained from healthy lung 
tissue from transplantation donors if only single-lung transplantation was performed, or from 
patients that had undergone lobectomy because of benign pulmonary tumours.
2.2 Ethical permissions (II, III, IV) 
In studies II, III, and IV, ethical permission was granted by the appropriate ethical 
committees of the respective institutes. Helsinki University Central Hospital permissions for 
clinical samples ((§29/2005 and §43/2006), and permissions from TEO for historical samples 
(Helsinki University Central Hospital #3296/32/300/05 and Oulu University Central Hospital 
# 5802/32/300/03). 
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3 METHODS 
3.1 Cell line studies (I, III, IV) 
A549 cells (American Type Culture Collection, Rockville, MD) were cultured in a nutrient 
mixture F-12 growth medium supplemented with 15% fetal bovine calf serum (FBS), 100 
U/ml penicillin and 100 mg/ml streptomycin at 37°C in a 5% CO2 atmosphere. Beas-2B cells 
(National Cancer Institute, Laboratory of Human Carcinogenesis) were cultured according to 
the recommended instructions (bronchial epithelial cell growth medium [BEGM]; Clonetics 
Inc., San Diego, CA). MeT-5A, M14K, and M38K cells were cultured using RPMI 1640 
medium supplemented with 10% heat inactivated FBS, 0.003% L-glutamine, 100U/ml 
penicillin, and 100 mg/ml streptomycin at 37°C in a 5 % CO2 atmosphere. 
Semiconfluent cell cultures were exposed to crocidolite (International Union Against Cancer, 
Johannesburg, South Africa) (2 μg/cm2 for A549 and Beas-2B cells and 1 μg/cm2 for MeT-
5A cells) for a series of time points, 1h, 6h, 24h, and 48h, and additional 7 days for A549. 
Samples  from  the  MeT-5A  cell  line  were  collected  at  1h  and  48h  from  exposed  and  non-
exposed control cells. Samples were collected from asbestos-exposed and control (not 
exposed parallel cultures) cells. The cultures and exposures were conducted on three or more 
separate culture plates and pooled before RNA extraction.  
Human SV40-immortalized pleural mesothelial (MeT-5A) cells (American Type Culture 
Collection, Rockville, MD, USA), and two MM cell lines, M14K and M38K were used and 
cultured  as  described  earlier.  The  cells  were  cultured  on  slides  (NUNC  A/S,  Roskilde,  
Denmark) coated with fibronectin, for immunocytochemistry (ICC). The cells were fixed 
with 4 % paraformaldehyde and stained with a commercial polyclonal rabbit GATA-6 
antibody (Santa Cruz Biotechnology inc., Santa Cruz, CA, USA) as described (Anttonen et 
al. 2005).
3.2 Gene expression (I) 
RNA was extracted and purified using Qiagen RNeasy kit (Qiagen Inc., Valencia, CA, USA) 
and RNA quality was measured using Agilent's BioAnalyzer (Agilent Technologies, Palo 
Alto, CA). The RNAs, including one replicate of any time-point for each cell line, were 
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hybridized to Affymetrix Human Genome U133 Plus 2.0 oligonucleotide microarrays 
(Affymetrix, Santa Clara, CA). Reverse transcription of 5 μg total RNA to cDNA was done 
using the Superscript Double Stranded cDNA Synthesis kit (Invitrogen, Paisley, UK). The 
cDNA was linearly amplified and in vitro transcription reactions using the BioArray high-
yield RNA transcript labeling kit (T7; Enzo Life Sciences, Farmingdale, NY) were carried 
out to produce biotinylated CTP and UTP labeled cRNA. Labeled and fragmented cRNA was 
then hybridized to the Affymetrix microarrays for 16h at 45ºC in a rotating oven (60 rpm). 
The arrays were washed and stained with streptavidin-phycoerythrin in a Fluidics station 450 
(Affymetrix I, Santa Clara, CA, USA: GeneChip Expression Analysis: Data Analysis 
Fundamentals. 2004), and scanned with Affymetrix GeneChip Scanner 3000. The image was 
analyzed using the GeneChip operating software (GCOS; Affymetrix, Sacramento, CA) and 
comparison analysis was done according to the instructions provided by the manufacturer. 
Data received from the microarrays are stored in the CanGEM database (www.cangem.org). 
3.2.1 Statistical analysis (I) 
To identify the relevant genes, three different statistical analyses were conducted. The arrays 
were pre-processed using Robust Multi-array Average (RMA) (Irizarry et  al. 2003), with 
default (i.e., quantile normalization) in the program R. 
The analysis for Gene Ontology (GO) annotation terms was done for all cell lines at each 
time point. The genes at every time point were rank-ordered according to their logarithmic 
fold-change values between asbestos exposed and non-exposed samples. Affected biological 
processes were determined by using the iGA algorithm (similar to (Breitling et al. 2004). For 
a given ontology class, iGA computed the minimal class-wise hypergeometric "p-value" (GO 
terms with permuted p-value of less than 0.01 were interesting). To detect the most specific 
processes, with the least genes affected, the GO terms were ordered into branches to form a 
tree-like structure where the processes in each branch are related. The truly affected 
processes should be detected at several levels of the tree. The identified branches with at least 
three affected terms were considered interesting. 
For the cluster analysis, the value for each probe set was calculated by subtracting the 
expression values measured in the non-exposed control from the values in the asbestos 
exposed sample at each time point. Probe sets were removed before cluster analysis, if none 
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of the time points showed an >1.4-fold (v2) difference between the non-exposed and exposed 
cases, if the probe sets did not have an associated gene title, and if the 
"present/marginal/absent" expression rating system used in Affymetrix microarray analysis 
software (Affymetrix, I., Santa Clara, CA, USA GeneChip expression analysis: data analysis 
fundamentals. 2004) (an open source implementation (Gautier et al. 2004) of the Affymetrix 
algorithms  was  used)  showed  a  probe  set  as  absent  in  all  microarrays  relevant  to  the  
experiment. A total of 19 710 out of the 54 675 different probe sets were included in the 
cluster analysis of at least one cell line. 
The reduced data set from each cell line was clustered using an algorithm designed for short 
time series expression data (Ernst et al. 2005). The total number of clusters was set to 50, and 
the algorithm labeled some as being statistically significant (p < 0.05, Bonferroni corrected) 
using a permutation test. 
The enriched GO as well as enriched chromosomal regions (both referred to as "terms" in the 
following) for each cluster were accounted for by calculating the probability of having at 
least  the  observed  number  of  probe  sets  associated  with  a  given  term,  assuming  a  random  
selection of probe sets. All 54 675 probe sets on the microarray were used as a reference set. 
The possible enrichment of the terms in different subsets (clusters) of the reference set was 
evaluated by computing p-values from the hypergeometric distribution. 
The canonical correlation analysis (CCA) (Palozza 2005) was performed on the A549 and 
Beas-2B cell lines. The MeT-5A cell line was not included due to the scarcity of time points. 
The method describes the shared variation between two data sets. Genes were arranged, 
according to their contribution to the dependencies of the two data sets, which were 
measured by the squared sum of CCA projection scores. Enrichment in 307 chromosome 
bands was tested (p-values were evaluated based on permutation test), and a list with affected 
chromosomal bands and genes was obtained.  
3.3 Lung and pleural specimens 
3.3.1 DNA extraction (II) 
Fresh-frozen and formaldehyde-fixed paraffin-embedded tissues were obtained from the 
Helsinki University Central Hospital, Archives of the Finnish Mesothelioma panel and 
London Royal Brompton Hospital, London, UK. Diagnosis was confirmed based on 
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histological characteristics and immunohistochemical (IHC) data. The tissue samples were 
homogenized and DNA was extracted by the standard phenol-chloroform method. DNA from 
pooled male and female peripheral blood lymphocytes was used as a reference for the 
analysis. DNA from paraffin-embedded tissue was extracted using standard protocols, and 
used for array CGH. Pooled male and female peripheral blood lymphocytes were used as 
reference DNA for the hybridizations.  
3.3.2 Array comparative genomic hybridization (II) 
DNA was digested with Alu I and Rsa I  enzymes (Sigma, St. Louis, MO, USA) and purified 
in QIAGEN MiniPrep columns (QIAGEN Inc., Valencia, CA, USA). The microarray 
platforms used contained 44,000 oligonucleotide probes representing both coding and non-
coding regions (Human 44B; Agilent Technologies, Palo Alto, CA, USA). DNA labeling, 
hybridization on microarrays, and slide washings were performed according to the 
manufacturer’s protocols. In brief, 1.5 g of purified, digested tumour and reference DNA 
were  labeled  with  Cy5  and  Cy3  (GE  Healthcare  Life  Sciences,  Buckinghamshire,  UK),  
respectively, using the BioPrime labeling kit (Invitrogen, Paisley, UK). The DNAs were 
hybridized on the array for 42 h at 65 ° C, which was subsequently washed and scanned with 
Agilent laser confocal scanner G2565AA (Agilent Technologies, Palo Alto, CA, USA). 
Data processing
The microarray image data was extracted using the Feature Extraction v8.1 software (Agilent 
Technologies) with Lowess normalization and local background subtraction to receive the 
fluorescence intensity ratios of the array features. Data received from the microarrays are 
stored in the CanGEM database (www.cangem.org) Data  were  analyzed  using  CGH  
Analytics v3.4 (Agilent Technologies, Palo Alto, CA, USA) with a z-score algorithm 
(threshold 2.5) and 0.5 – 1 Mb moving average window. The tumour-to-normal intensity 
ratios  were  given  as  fold  changes  in  the  graphical  output,  with  the  fold  change  ‘zero’  
corresponding to equal copy numbers in tumour and control DNA. Due to the below-optimal 
( < 70%) tumour cell content of some tissue samples, fold change values above +0.3 x and 
below –0.3 x given by the software were considered as gains and losses, respectively.  
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3.3.3 Real-time RT-PCR (III) 
RNA was extracted using Qiagen RNeasy min kit (Qiagen, Inc., Valencia, CA, USA), and 
reverse transcription by Superscript II reverse scriptase kit (Invitrogen, Carlsbad, CA, USA). 
The levels of gene expression were determined using TaqMan Assays-on-Demand gene 
expression products (Applied Biosystems, Foster City, CA) and GeneAmp 7500 Sequence 
Detector thermal cycler (Applied Biosystems).  
3.3.4 Immunohistochemistry (IHC) and immunocytochemistry (ICC) (III, IV)  
Paraffin-embedded tissue samples spotted on the slides were deparaffinised in xylene and 
dehydrated in graded alcohol. The sections were subjected to IHC using commercial 
polyclonal rabbit anti GATA-6 IgG at a dilution of 1:100 (Santa Cruz Biotechnology inc., 
Santa Cruz, CA).  The specificity of the staining was assessed using PBS or rabbit isotope 
labelling (ZYMED, San Fransisco, CA, USA), instead of the primary antibody during the 
staining protocol. The avidin-biotin immunoperoxidase system was used according to the 
manufacturer’s instructions (Vectastain Elite ABC Kit, Vector Laboratories Inc., 
Burlingame, CA). Staining was done using DAB (Vector Laboratories Inc., Burlingame, 
CA), and counterstaining with hematoxylin. Two pathologists scored the slides 
independently. GATA-6 nuclear and cytoplasmic staining was scored negative, weakly 
positive (<50%), or strongly positive (>50%), and distinct MM subtypes were taken into 
consideration.  Cytoplasmic staining was scored but not taken into consideration in the final 
results.  
Gremlin was stained using Zymed ABC Histostain-Plus kit (Zymed, South San Francisco, 
CA)  or  Vectastain  Elite  ABC  kit  (Vector  Laboratories,  Burlingame,  CA),  according  to  the  
manufacturer’s protocol. Before staining, antigens were retrieved by heating the sections in 
citrate buffer. 
3.4 Mouse model – Asbestos induced pulmonary fibrosis (III) 
Progressive pulmonary fibrosis was induced in C57BL/6 mice with a 0.1 mg dose of 
intratracheally instilled crocidolite asbestos (National Institute of Environmental Health 
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Sciences, Research Triangle Park, NC) and using titanium dioxide (Sigma, St. Louis, MO) as 
a control (previously described in Fattman et al. 2006) . The mice were killed on day 3 or 14 
(five/group). BMP-7 was administered to asbestos-treated mice intraperitoneally at a dose of 
300 μg/kg/injection from day 7 to 14. BMP-7–treated mice were killed on day 14.
3.4.1 Hydroxyproline assay (III) 
The analyses were performed as previously described (Tan et al. 2004). Briefly, the right 
lungs were dried for 48 hours and acid hydrolyzed in oxygen-free glass ampoules, containing 
2 ml of 6 N HCl, at 110°C for 24 hours. Hydroxyproline was quantified using chloramine T.  
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4 RESULTS AND DISCUSSION 
4.1 Differentially expressed genes in asbestos-exposed lung cell lines (I) 
Since MM is a cancer with a dismal prognosis; by the time of diagnosis usually most often 
no therapies are able to cure the disease. Thus early detection is of the utmost importance. 
The aim was to study asbestos-related early changes in human cell lines exposed to asbestos, 
by comparing three human lung cell lines exposed to asbestos versus non-exposed cultured 
cells. Numerous previously known as well as new genes and biological processes were 
recognized. By comparing and identifying changes common to all cell lines, some of the 
expression changes associated with the malignancy or the cell type could be overlooked and 
it was possible to concentrate on specific asbestos-related changes. 
Asbestos is cytotoxic in vitro (especially to human mesothelial cells), and does not directly 
cause malignant transformation (Carbone et al. 2002; Yang et al. 2003). Normal mesothelial 
cells are very hard to culture, therefore the most commonly used reference for MM cell 
culture studies, is the SV40 transformed MeT-5A cell line. Since the asbestos exposure 
experiments were designed as a time series to aid in profiling biological processes and genes 
at different stages of exposure, a huge amount of data was obtained. By combining data from 
three different human lung cell lines, the aim was to find specific asbestos evoked cell 
damage, instead of random changes in gene expression profiles, and to eliminate the 
modification attributable to SV40-immortalized cell lines. 
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Figure 6. Expression profiling analysis work flow, and combination of data. Abbreviations: 
GO = Gene ontology, CCA = canonical correlation analysis. 
4.1.1 Statistical analysis reveals asbestos-associated gene expression profiles in human 
lung cell lines (I)  
Careful selection of the design and evaluation of bioinformatics methods used for microarray 
experiments is very important. The results depend on the references used, sample handling, 
normalization, and statistical analysis methods. In this study, three different bioinformatics 
approaches were used to study up- and down-regulated biological processes and genes.  
The GO analysis was used to obtain a rough estimation of differentially commonly expressed 
genes  due  to  asbestos  exposure.  GO  processes  which  were  common  for  all  cell  lines  were  
studied at each time point. The common GO terms were considered as interesting based on 
the  permutated  p-value,  and  as  a  way  to  detect  the  most  detailed  processes,  the  GO  terms  
were ordered in branches. Affected processes should be detected on several levels, and 
processes with p<0.01 were considered important. Down-regulated processes after 48 h 
included “positive regulation of transcription, DNA-dependent”, “cytoplasmic sequestering 
of NF-B”, and “regulation of MAPK activity” (p< 0.005). Most processes were down-
regulated at 48 h, even though up-regulation could be observed at an earlier stage, at 6 h.  
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Although single genes in this kind of profiling experiments are of minor importance, an 
enourmous amount of data obtained was generated, and the GO terms included up to 85 
genes. The study provides the possibility to have an overview of the processes involved, and 
can pinpoint further potential targets for functional research. 
Each cell line profile was separately studied with cluster analysis, and the clusters of GO 
terms and genes at each time point in each cell line were arranged in an order based on 
significance. The most significant clusters from each cell line and GO terms found in all 
clusters linked to the GO analysis were selected. The GO terms "negative regulation of 
survival gene product activity" and "positive regulation of transcription, DNA-dependent" in 
the significant clusters, were also found in the GO analysis. In the term "positive regulation 
of transcription, DNA-dependent" genes such as RUNX1, GATA4, SMARCC1 and CTNNB1
among 848 other genes were down-regulated, whereas "cytoplasmic sequestering of NF-B"
contained genes FAF1, IL10, G3BP2, NFKBIA and BCL3. Preveously RUNX1 has been 
claimed to be down-regulated in asbestos-related lung cancer (Wikman et al. 2007), and 
involved in translocations, and it has been proposed to act as either a TSG or as an oncogene 
also in other cancers (Blyth et al. 2005). Members of the GATA transcription factor family 
have also been implicated in various cancers, and will be described later in more detail in 
relation to MM. Wnt signaling activity has been studied in MM (Uematsu et al. 2003), and 
studies on CTNNB1 in lung cancer and MM have pointed to a TSG role for the gene 
(Shigemitsu et al. 2001).  
The CCA analysis was used to identify genes that contribute to the dependencies between the 
A549 and Beas-2B cell lines. The aim was to conduct a more robust analysis to find 
chromosomal bands enriched by genes affected by asbestos exposure. When these bands 
were correlated with the results from copy number studies in asbestos-related cancer, 
similarities and more specific break points was obtained. The chromosomal regions 2p22, 
9p13, and 14q21 were common for all analyses, and 9p13, and 14q21 have been associated 
with MM (Ivanov et al. 2009). These sites obtain genes such as MAP4K3, FANCG, 
IGFBPL1, FANCM and CDKL1. Genes involved in the MAPK pathway are well known to 
be up-regulated by asbestos (Mossman et al. 1997).
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The specific genes common for all analyses were the thioredoxin domain containing gene 
(TXNDC) and the potential tumour suppressor, BCL2/adenovirus E1B 19kD-interacting 
protein gene (BNIP3L),  GO-terms  "positive  regulation  of  I-B  kinase/NF-B  cascade"  and  
"positive regulation of transcription, DNA-dependent", and chromosomal regions 2p22, 
9p13, and 14q21.
BNIP3L is a proapoptotic BCL2 family protein and it is a member of the BCL2/adenovirus 
E1B 19 kd-interacting protein (BNIP) family. It interacts with the E1B 19 kDa protein which 
is responsible for protection against virally-induced cell death, and also with E1B 19 kDa-
like sequences of BCL2, which is an apoptotic protector. The protein encoded by this gene is 
a functional homolog of BNIP3, a proapoptotic protein. This protein may function 
simultaneously with BNIP3 and may play a role in tumour suppression. BNIP3L suppresses 
tumour growth in xenografts and is a mediator of p53 dependent apoptosis during hypoxia 
(Fei et al. 2004).
The thioredoxin domain containing (TXNDC) gene was found to be a common result for all 
cell lines and methods. Thioredoxin (TRX) and thioredoxin reductase (TXNR) have been 
studied in MM (Kahlos et al. 2001). With both the mRNA and the protein levels were 
elevated in the specimens. These thioredoxins might be induced by ROS. TRX stimulates 
cell proliferation and reduces apoptosis of cancer cells, at least in vitro. Rihn et al. (2000) 
showed that MM cells over-expressed TRX (Rihn et al. 2000). For this study, real-time PCR 
was performed for TRX and TRXR on RNA from SV40 mesothelial cell line and two MM 
cell lines (M14K, M38K). TRX and TRXR were investigated and shown to be up-regulated in 
the MM cell lines compared to the normal MeT-5A cell line (unpublished results).  
In a similar, but not comparable cell line profiling study (Hevel et al. 2008), A549 cells were 
exposed to asbestos at a concentration of 6 g/cm2, instead of 2 g/cm2 as used in Study I. 
These  results  did  not  detect  the  similar  results,  but  on  the  other  hand  the  study  was  not  
designed in the same way, and only one cell line exposed to asbestos was evaluated. They 
found that a majority of the differentially expressed genes were up-regulated, verified some 
of the genes by quantitative RT-PCR, and found the microarray results to be very 
reproducible. The up-regulated genes verified by RT-PCR were EGR1, ATF3, c-Jun and 
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JunB (Hevel et al. 2008). This cannot be directly compared with this study, since different 
kinds of bioinformatical methods and furthermore only one cell line was used. 
4.2 DNA copy number changes in MM (II) 
Karyotypic  alterations  have  been  published  for  MM  and  revealed  a  recurrent  pattern  of  
chromosomal aberations (Bjorkqvist et  al. 1997; Bjorkqvist et al. 1998; Krismann et al.
2002). Genomic profiling with high-density oligo-nucleotide arrays for CGH analysis 
enables the determination of genome wide copy number changes. Our results of DNA copy 
number changes by CGH confirmed previous chromosomal aberrations reported in MM. 
Array CGH studies have revealed novel recurrent aberrations in MM (Taniguchi et al. 2007) 
and several potential target genes. The aim of this study was to profile the copy number 
changes  in  MM samples,  and  to  gather  data  of  preferentially  lost  and  gained  chromosomal  
regions for further analysis. 
This study demonstrated the use of the oligonucleotide array CGH platform, in MM DNA 
copy number profiling, and although not providing of the functional roles of genes involved, 
it still provided a basis for identifying potential new targets, as well as confirming old ones. 
One aspect that should be taken into consideration is the use of paraffin embedded material. 
The different parts of the tumour could also be evaluated more exactly by performing laser 
microdissection, and separation of the stroma from the tumour cells. We decided to use 
samples with a tumour percent of over 50%.  
The most commonly detected recurrent DNA copy number change was a loss/deletion at 
9p21.3, followed by losses of 6q22.1, 1p31.1p13.2, 3p22.1p14.2, 14q22.1qter, 13cenq14.12 
and 22cenq12.3. Each sample contained numerous copy number changes, especially losses. 
Since most of the samples belonged to the epithelioid subtype, subtype specific changes 
could not be determined with certainty. Previously, most array CGH studies of MM have not 
separated the distinct MM subtypes, but Krisman et al. (2002) did compare the subtypes, and 
revealed that 3p, 7q, 15q, and 17p displayed significant variation between the epitheliod and 
sarcomatoid subtypes. Epithelioid and sarcomatoid MM do seem to show different 
pathogenesis, therefore the different subtypes should be taken into consideration when 
analyzing any kind of data. In this study, the sarcomatoid subtype represented a minority of 
eight samples. The most common gain in the epithelioid subtype was at 17q21.32qter, but in 
Results and Discussion 
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
53
the sarcomatoid subtypes gains at 5p could also be observed. The gained region included 
genes MAP3K3, SMARCD2, ERN1 and PRKCA. The MAPK pathway is well known to be 
up-regulated in MM, as are the protein kinase C (PKC) family of serine- and threonine-
specific protein kinases that can be activated by calcium. The PKC signal transduction 
pathway is believed to be one of the main signaling pathways to be activated after asbestos 
exposure (Shukla et al. 2003b). 9p13 was found to be gained in some samples, and the region 
was also found in CCA results of study I, as was described in another array CGH study 
(Ivanov et al. 2009). Another region frequently altered in MM is 14q21, which was also one 
of the highly significant regions of the CCA results (I).
The biological processes, such as "positive regulation of transcription, DNA-dependent" and 
"negative regulation of survival gene product activity", seen in the cluster and GO analyses, 
were also compared with the genes in the regions of the CCA (I). The regions, such as 2p22 
revealed  in  the  CCA  analysis,  are  not  exactly  the  same  as  previously  found  in  asbestos-
related lung cancer and MM, but could reflect changes in asbestos-related diseases.  
The chromosomal regions revealed in various CGH studies are similar, but the breakpoints 
vary across samples and studies. Therefore, it might be important to try to elucidate the 
central minimal regions involved in the majority of the samples/studies. In this study, the 
minimal common regions of the most recurrent changes were 1p31.1p13.2, 3p22.1p14.2, 
6q22.1, 9p.21.3, 13cenq14.12, 14q22.1qter, 17q21.32 and 22cenq12.3. Deletion or loss of 
9p21.3 is a frequent event in MM, and especially deletion of CDKN2A, which is usually co-
deleted with CDKN2B and MTAP has been correlated with unfavourable survival (Ivanov et 
al. 2009; Lopez-Rios et al. 2006). Another commonly known lost/deleted gene at 22q is NF2,
which is mutated in 40 % of the MM cases (Bianchi et al. 1994; Sekido et al. 1995). A new 
potential target gene OSM, belonging to the cytokine family at 22q was pinpointed (Ivanov et 
al. 2009).  A region which was only recently reported in other studies of MM positioned at  
19q13.32 and deleted in the majority of the samples (Ivanov et al. 2009), and in this study 
loss of chromsome 19 was found in 19% of the studied samples. Aberrations in 19p13 have 
been reported in asbestos-related lung cancer with allelic imbalance in 19p being prevalent 
regardless of the histological tumour type (Ruosaari et al. 2008). 
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4.3 The BMP-antagonist gremlin is up-regulated in asbestos-exposed lung epithelial 
cells (III) 
Since asbestos causes asbestosis, differentially expressed genes in the lung epithelial cell line 
from the asbestos-treated samples were further studied, and revealed that the BMP antagonist 
gremlin was notably up-regulated after 6 h of asbestos exposure (Figure 7). The up-
regulation  of  gremlin  was  not  included  in  any  of  the  statistical  results  of  Study  I,  but  was  
found to vary between asbestos-exposed cells compared to the non-exposed counterparts in 
the normalized data set (RMA data). Gremlin is known to be up-regulated in pulmonary 
fibrosis (Koli et al. 2006). In study III, asbestos induced up-regulation of gremlin, was 
studied in cell cultures using human epithelial cells and lung bronchial cells, as well as 
mouse inhalation experiments. The study confirmed up-regulation of gremlin in A549 cells 
in vitro.
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Figure 7. A) The RMA data from the cell line study revealed up-regulation of gremlin at 6 h 
in the A549 cell line. B) IHC of gremlin (x 300) in MM displayed staining in cancer cells 
(Unpublished results). 
The crocidolite asbestos–induced model of fibrosis is progressive and has similar temporal 
characteristics to human UIP lesions. Commonly used models in lung fibrosis research 
include radiation damage, instillation of bleomycin, silica or asbestos, and transgenic mice or 
gene transfer employing fibrogenic cytokines (reviewed in Moeller et al. 2008). One of the 
standard agent for induction of experimental pulmonary fibrosis in animals has been 
bleomycin, but there is a clear need for model improvement, since IPF is very complicated, 
and the etiology and natural history of the disease is unclear. Here the asbestos-induced 
pulmonary fibrosis model proved to be most valuable. 
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4.3.1 Down-regulation of BMP signaling by gremlin (III) 
Members of the TGF- family, including TGF-, activin, nodal and BMPs, are 
multifunctional cytokines that regulate a range of cellular responses, including cell 
proliferation, differentiation, adhesion, migration and apoptosis (Feng and Derynck 2005). 
Exposure to asbestos, up-regulation of gremlin and the consequent decrease of BMP 
signaling, resulted in lung fibrosis in mice. The down-regulation of BMP signaling activity 
resulted in asbestos induced pulmonary fibrosis in mice. Its histopathology resembles UIP, 
and therefore it can be used as a fibrosis model instead of the widely used bleomycin model. 
Titanium dioxide (TiO2), which has been shown to be incapable of inducing induce fibrosis, 
was used as a control. In contrast to gremlin, the BMP antagonists noggin and chordin were 
not up-regulated in the response to asbestos-exposure in the mouse model. The up-regulation 
of gremlin in mice at 14 days after exposure is in concordance with previous results of up-
regulation of gremlin in IPF patients (Koli et al. 2006). The results were studied on both 
mRNA and protein levels. In tissue sections, gremlin immunoreactivity was especially 
localized to the epithelium adjacent to fibroblastic lesions.  
Whereas no changes in the BMP mRNA levels were detected, BMP target genes Id1 and Id2
were examined, and the Id1 mRNA levels were significantly reduced in lung tissue. Since 
canonical signaling of BMPs proceeds with phosphorylation of Smad1/5/8, these were 
examined by IHC in relation to the inert control.  
In addition to up-regulation of gremlin in lung fibrosis, this phenomenon has been reported in 
kidney and liver fibrotic disease (Boers et al. 2006; Dolan et al. 2005). Furthermore in cancer 
gremlin has also been shown to be up-regulated, and BMP signaling has been suggested to 
inhibit tumourigenesis in several tumour types (Sneddon et al. 2006).
4.3.2 TGF- activity by asbestos fibres in lung fibrosis (III) 
TGF- activity can be induced by asbestos fibres (Pociask et al. 2004), which was also the 
case in this study where asbestos increased TGF- activity. Since TGF- expression regulates 
gremlin in human lung (Koli et al. 2004), inhibition of TGF-RIs noted in in vitro
experiments in this study, also prevented asbestos induced gremlin mRNA expression. On 
the other hand treatment with exogenous TGF-1 induced the expression of gremlin. 
Results and Discussion 
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
56
In the fibrosis mouse model, mRNA expression of TGF- was not notably up-regulated 
compared to the TiO2 model, but when TGF- activity was investigated further, it was found 
that the level of plasminogen activator (PAI-1) which is a TGF- target gene, was up-
regulated. The protein expression level of P-Smad-2 was examined by IHC and 
immunoblotting and was not surprisingly up-regulated as well as being localized around the 
asbestos fibres and fibrotic areas. 
The MAPK pathway that has been studied in asbestos-related diseases was inhibited in the 
normal human bronchial epithelial cell line NHBE before exposure to asbestos. This blocked 
the gremlin mRNA expression, suggesting that the MAPK pathway plays an important role 
in asbestos induced fibrosis.  
4.3.3 BMP-7 treatment of lung fibrosis patients? (III)  
IPF  is  typically  progressive,  with  a  median  survival  of  2  to  5  years  from  the  time  of  
diagnosis. Medical therapy is ineffective in the treatment of IPF, and IPF/UIP does not 
respond to any anti-inflammatory therapy. New molecular therapeutic targets have been 
identified and several clinical trials are investigating their efficacy. Pulmonary 
transplantation remains a viable option for patients with IPF. 
The results indicated that TGF- and BMP signaling balance is important for lung 
regenerative events and is significantly disturbed in pulmonary fibrosis. Restoration of BMP 
signaling activity may represent a novel approach for treating human pulmonary 
fibrosis/asbestosis. Since asbestosis displays similar features as IPF, this model can represent 
pathways for asbestos-induced murine model of fibrosis as well as for asbestosis in the lung.  
4.4 Expression of GATA-6 and its significance in MM and metastatic pleural 
adenocarcinoma (IV) 
The GATA transcription factors have been reported to associate with TGF- signaling in the 
immune system and the heart (Blokzijl et al. 2002; Brown et al. 2004). TGF-1 is known to 
be up-regulated by asbestos (Dai and Churg 2001; Liu and Brody 2001), and therefore also 
GATA-6 could have a role in asbestos-related diseases. Tenascin (TNC), an important 
regulator of cell adhesion, migration and proliferation during carcinogenesis, contains several 
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putative GATA-6 binding sites, and GATA-6 is believed to be a repressor of TNC
(Ghatnekar and Trojanowska 2008). 
The transcription factor GATA-6 was identified to be over-expressed in MM and metastatic 
pleural adenocarcinoma. The expression was specifically localized to the nucleus, with a 
stronger expression in the MM samples. The role of GATA-6 is emerging in various cancers, 
and has been described in lung cancer, pancreatic carcinoma (Fu et al. 2008a) and ovarian 
carcinoma (Mannisto et al. 2005; McEachin et al. 2008). 
In this study we did not examine other GATA transcription factors such as GATA-4. Studies 
on hypermethylation point to down-regulation of GATA4 and GATA5, but not of GATA6 
(Guo et al. 2004b; Guo et  al. 2006). This is in accordance with other studies investigating 
GATA transcription factors in cancer (Guo et al. 2004a; Mannisto et al. 2005). 
The GATA-6 IHC results of MM and adenocarcinoma do not cause problems in the 
differential diagnostics, but markers for prediction of prognosis could benefit clinicians to 
predict the survival of the patient. However, the prediction of prognosis for patients within a 
specific subgroup is less clear and not straightforward for the clinician to predict. The 
patients  with  epithelioid  subtype  have  a  significantly  better  prognosis  than  the  sarcomatoid  
subtype, and respond better to therapy, although the patients are not cured. 
4.4.1 Over-expression of GATA-6 in MM and metastatic pleural adenocarcinoma 
implies longer survival in epithelioid and sarcomatoid MM (IV) 
Prognostic markers (see chapter 2.3) have been sought for MM patients, but today, none of 
the markers are in clinical use. Factors such as epithelioid subtype, younger age and no 
asbestos history indicate favorable prognosis. 
There was no significant correlation between expression of GATA-6 and proliferation and 
apoptosis in this sample set. Apoptosis as well as proliferation rarely occurs in MM 
histological samples. 
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GATA-6 expression correlated with a favorable prognosis in epithelioid and sarcomatoid 
MM. MM-B which  is  a  mixture  of  these  two subtypes  should  therefore  also  correlate  with  
longer survival. In this study, expression of GATA-6 did correlate with longer prognosis, 
probably due to the small number of MM-B cases. The majority of the epithelioid MM cases 
showed strong expression of GATA-6, and < 5 % showed no staining. Of the metastatic 
adenocarcinoma samples, only 8 % displayed strong expression. However, the results were 
based on both strong and weak expression, and clearly pointed to longer survival in 
epithelioid- and sarcomatoid patients presenting GATA-6 expression. TTF-1 is an epithelial 
marker used in differential diagnosis. TTF-1 is required for the peripheral lung 
alveolarisation and for the expression of various epithelium-specific genes in the respiratory 
system.  GATA-6  and  TTF-1  physically  interact  and  for  example  regulate  expression  of  
surfactant proteins (Bruno et al. 2000; Shaw-White et  al. 1999).  MMs are 100 % negative 
for TTF-1, but expression of GATA-6 was correlated with TTF-1 expression in the 
metastatic pleural adenocarcinoma cases, but no statistically significant correlation was 
found.  
GATA transcription factors are widely expressed and studied during development. Several 
studies now report involvement of GATA-6 in malignancies. The data obtained here provides 
support for the involvement of GATA-6 in MM and metastatic pleural adenocarcinoma. 
Although this needs further research, we could conclude that GATA-6 was strongly 
expressed in MM tumors, and the expression of GATA-6 significantly correlated with longer 
survival in this sample set of tumors. 
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5 CONCLUSIONS AND FUTURE PROSPECTS 
This thesis provides an overview on genomic and expression profiling in asbestos-related 
lung diseases, with the focus on MM, which is the disease most strongly linked to previous 
asbestos exposure and lung fibrosis. The aim was to profile asbestos-related changes, both in 
pleural and parenchymal lung diseases. Profiling of potential new asbestos related markers 
was performed by using microarrays for gene expression and DNA copy number detection, 
and by further investigating asbestos affected pathways. 
The results summarized here confirmed some earlier identified genomic changes, but also 
clearly extended previous observations about asbestos induced changes in human lung, and 
selected some potential markers for asbestos induced pulmonary fibrosis. By combining 
different microarray platforms, bioinformatics, and pathway studies, this study could 
elucidate genetic changes associated with asbestos fibre burden both in vitro and in vivo.
Changes in asbestos-induced differential gene expression were studied using three human 
lung cell lines as well as different bioinformatical approaches. In addition to earlier 
recognized alterations, this study did reveal changes not previously described as asbestos-
associated. Asbestos-induced alterations included changes in regions such as 2p22, 9p13 and 
14q21, aberrant expression of biological processes "positive regulation of I-B kinase/NF-B
cascade" and "positive regulation of transcription, DNA dependent", as well as genes 
TXNDC and BNIP3L.
DNA copy number changes in MM tumours were assessed using whole-genome 
oligonucleotide microarrays. Previous cytogenetic analyses have revealed a complex nature 
of gains and losses of chromosomes. The changes in the majority of the samples were 
numerous, and mostly involved broader areas of copy number change. Microdeletions / 
losses could be observed at 9p21.3 including CDKN2A,  which  was  also  the  most  frequent  
alteration. Other recurring prominent losses were 1p31.1p13.2, 3p22.1p14.2, 6q22.1, 
13cenq14.12, 14q22.1qter, and 22qcenq12.3. Previously unreported gains were found at 
9p13.3, 7p22.3p22.2, 12q13.3, and 17q21.32qter. Although MMs have a fairly typical 
patterns of cytogenetic defects, there is no one chromosomal abnormality that is specific. 
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The finding that gremlin was up-regulated at 6 h in response to asbestos exposure in the 
epithelial cell line A549 was verified by real-time PCR as well as in another epithelial cell 
line. The role of gremlin in BMP signaling in pulmonary fibrosis was studied in asbestos 
exposed cells in vitro and in mice models in vivo. These studies further revealed deregulation 
of BMP-7 signaling in fibrosis and prevention of fibrosis progression by BMP-7 in vivo.
Members of the TGF- family are crucial for the maintenance of tissue homeostasis and 
regeneration of injury. Thus imbalance of the TGF- and BMP signaling may lead to 
progression of IPF. Restoration of BMP-7 is a potential treatment option for human IPF. 
The prognosis of MM is very poor. The last part of this study suggests that the expression of 
GATA-6 correlates with longer prognosis in subgroups of MM. The results will require 
further investigation, but the expression of GATA-6 was strongly positive especially in the 
tissues of MM. TTF-1 is widely used in the differential diagnostics of MM and metastatic 
adenocarcinoma, and implicated as a co-factor for GATA-6; no correlation between GATA-6 
expression and TTF-1 staining could be detected. The involvement of the transcription factor 
GATA-6 in MM carcinogenesis needs further investigation. 
Asbestos-related diseases are complex, mostly incurable and their numbers are still 
increasing all over the world. The microarray data in these and other studies are mostly 
deposited in publicly available databases. This gives researchers the possibility for in silico
and integration analysis, from where potential new markers can be selected and verified 
using molecular biology tools.  
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